<SEC-DOCUMENT>0001193125-18-128947.txt : 20180424
<SEC-HEADER>0001193125-18-128947.hdr.sgml : 20180424
<ACCEPTANCE-DATETIME>20180424165903
ACCESSION NUMBER:		0001193125-18-128947
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180424
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180424
DATE AS OF CHANGE:		20180424

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		18771994

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d575619d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of The Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): April 24, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>SANGAMO THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">000-30171</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">68-0359556</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>501 Canal Blvd., Richmond, California 94804 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(510) <FONT STYLE="white-space:nowrap">970-6000</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former Address, if changed since last report) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to Rule <FONT STYLE="white-space:nowrap">13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Emerging growth company&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or
revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this report, &#147;Sangamo,&#148; &#147;the Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148;
refer to Sangamo Therapeutics, Inc., a Delaware corporation, and its subsidiaries on a consolidated basis. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;2.02 Results of Operations and
Financial Condition. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On April&nbsp;24, 2018, Sangamo filed with the U.S. Securities and Exchange Commission (the &#147;SEC&#148;) a preliminary
prospectus supplement (the &#147;Preliminary Prospectus&#148;) pursuant to Rule 424(b) under the Securities Act of 1933, as amended, relating to its Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File No. 333-224418)
filed with the SEC on April&nbsp;24, 2018, in connection with a proposed public offering. In the Preliminary Prospectus, Sangamo disclosed that, as of March&nbsp;31, 2018, it had approximately $234.9&nbsp;million of cash, cash equivalents and
investments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Forward-Looking Statements </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Item&nbsp;2.02 of this report contains&nbsp;forward-looking statements, including, without limitation, statements relating to Sangamo&#146;s preliminary
unaudited cash and marketable securities position as of March&nbsp;31, 2018. These forward-looking statements are based upon Sangamo&#146;s current expectations. Actual results could differ materially from these forward-looking statements&nbsp;as a
result of certain factors, including, without limitation, risks related to preliminary financial results, including the risks that the preliminary financial results reported herein reflect information available to Sangamo only at this time and may
differ from actual results, including in connection with Sangamo&#146;s completion of financial closing procedures. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.
Sangamo undertakes no duty to update such information except as required under applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information contained in Item 2.02 of this report
shall&nbsp;not be deemed &#147;filed&#148; for purposes of Section&nbsp;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as
amended. The information contained in Item&nbsp;2.02 of this report&nbsp;shall&nbsp;not be incorporated by reference into any filing with the SEC made by Sangamo whether made before or after the date hereof, regardless of any general incorporation
language in such filing. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;8.01 Other Events. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sangamo is filing information for the purpose of supplementing and updating certain aspects of the description of its business from that described under the
heading, &#147;Item 1. Business&#148; in Sangamo&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, filed with the SEC on March&nbsp;1, 2018. The updated disclosure is filed herewith
as Exhibit 99.1 and is incorporated herein by reference. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Item&nbsp;9.01 Financial Statements and Exhibits. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(d) Exhibits </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:28.45pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Number</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d575619dex991.htm">Updated Company Disclosure </A></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">DATE: April&nbsp;24, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">SANGAMO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ HEATHER TURNER</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Heather Turner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and General Counsel</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d575619dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B></B><B><I>EXHIBIT 99.1</I></B><B> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Throughout this Exhibit 99.1, unless the context indicates otherwise, the terms &#147;Sangamo,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148;
refer to Sangamo Therapeutics,&nbsp;Inc., a Delaware corporation, and its subsidiaries on a consolidated basis. SANGAMO<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, SANGAMO
THERAPEUTICS<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Better Therapeutics By Design<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, ZFP Therapeutic<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, Engineering
Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and Pioneering Genetic Cures<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP><SUP STYLE="font-size:85%; vertical-align:top"> </SUP>are our registered trademarks in the
United States. All other trademarks or trade names referred to in this Current Report <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;8-K&nbsp;are&nbsp;the</FONT> property of their respective owners. </I></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPANY OVERVIEW </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Business
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform
patients&#146; lives using our industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. We
have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA
sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, we
have accrued significant scientific, manufacturing and regulatory capabilities and <FONT STYLE="white-space:nowrap">know-how</FONT> that are generally applicable in the broader field of gene therapy and have capitalized this knowledge into a
conventional gene therapy platform based on adeno-associated viral vector, or AAV, cDNA gene transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our strategy is to maximize the
value and therapeutic use of our technology platforms. In certain therapeutic areas we intend to capture the value of our proprietary genome editing and gene therapy products by forward integrating into manufacturing, development and commercial
operations. In other therapeutic areas we intend to partner with biopharmaceutical companies to develop products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on the
development of human therapeutics for diverse diseases with well-characterized genetic causes. We have several proprietary clinical and preclinical product candidates in development and have strategically partnered certain programs with
biopharmaceutical companies to obtain funding for our own programs and to expedite clinical and commercial development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have an
ongoing Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">SB-525,</FONT> a gene therapy for the treatment of hemophilia A, a bleeding disorder. We also have ongoing Phase 1/2 clinical trials evaluating three product candidates
using our&nbsp;proprietary <I>in vivo</I>&nbsp;genome editing approach: <FONT STYLE="white-space:nowrap">SB-FIX</FONT> for the treatment of hemophilia B, a bleeding disorder; <FONT STYLE="white-space:nowrap">SB-318,</FONT> for the treatment of
Mucopolysaccharidosis Type I, or MPS I; and <FONT STYLE="white-space:nowrap">SB-913</FONT> for the treatment of Mucopolysaccharidosis Type II, or MPS II. MPS I and MPS II are rare lysosomal storage disorders, or LSDs.&nbsp;We are also initiating a
Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">ST-400,</FONT> developed using our proprietary <FONT STYLE="white-space:nowrap">ZFN-mediated</FONT> <I>ex vivo</I> cell therapy platform, for the&nbsp;treatment of
beta-thalassemia, a blood disorder. In addition, we have proprietary preclinical and discovery stage programs in other LSDs, hematological disorders and monogenic diseases, including certain central nervous system, or CNS, disorders, cancer
immunotherapy, immunology and infectious disease. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma,
Inc., or Kite, a wholly owned subsidiary of Gilead Sciences, Inc., or Gilead, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we will work together with Kite on a research
program under which we will design ZFNs and AAVs to disrupt and insert certain genes in T cells and natural killer, or NK, cells, including the insertion of genes that encode chimeric antigen receptors, or CARs,
<FONT STYLE="white-space:nowrap">T-cell</FONT> receptors, or TCRs and <FONT STYLE="white-space:nowrap">NK-cell</FONT> receptors, or NKRs, directed to mutually agreed targets. Kite will be responsible for all clinical development and
commercialization of any resulting products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into a new research collaboration and license agreement with
Pfizer Inc., or Pfizer, for the development and commercialization of potential gene therapy products that use ZFP TFs to treat amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations of the
<I>C9ORF72</I> gene. Under this agreement, we are working with Pfizer on a research program to identify, characterize and preclinically develop ZFP TFs that satisfy <FONT STYLE="white-space:nowrap">pre-agreed</FONT> criteria. Pfizer is responsible
for subsequent development, manufacturing and commercialization of licensed products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2017, we entered into a global collaboration
and license agreement with Pfizer for the research, development and commercialization of <FONT STYLE="white-space:nowrap">SB-525,</FONT> our gene therapy product candidate for hemophilia A, and closely related products. Under this agreement, we are
responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for <FONT STYLE="white-space:nowrap">SB-525,</FONT> while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and
commercialization of <FONT STYLE="white-space:nowrap">SB-525.</FONT> We and Pfizer may also collaborate in the research and development of additional <FONT STYLE="white-space:nowrap">AAV-based</FONT> gene therapy products for hemophilia A. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have also established a collaborative partnership with Bioverativ, Inc., or Bioverativ, a wholly owned subsidiary of Sanofi, to research,
develop and commercialize therapeutic gene-edited cell therapy products in hemoglobinopathies, including beta-thalassemia and sickle cell disease, or SCD. We expect to begin enrolling patients in a Phase 1/2 clinical study for beta-thalassemia in
the first half of 2018. Bioverativ is responsible for subsequent development, manufacturing and commercialization of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have a substantial intellectual property position in the genome editing field including the design, selection, composition and use of
engineered ZFPs to support our research and development activities. As of February&nbsp;15, 2018, we either owned outright or have exclusively licensed the commercial rights to over 860 patents issued in the United States and foreign jurisdictions,
and over 610 patent applications pending worldwide. We continue to license and file new patent applications that strengthen our core and accessory patent portfolio. We believe that our intellectual property position is a critical element in our
ability to research,&nbsp;develop and commercialize products and services based on genome editing, gene therapy, gene regulation and cell therapy. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Product Development </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g575619g13d40.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemophilia A and B </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Hemophilia is a rare bleeding disorder in which the blood does not clot normally. It is also a monogenic disease, or a disease that is caused
by a genetic defect in a single gene. There are several types of hemophilia caused by mutations in genes that encode factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding
episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most severe forms of hemophilia affect males. The standard treatment for individuals with hemophilia is replacement of the defective
clotting factor with regular infusion of recombinant clotting factors or plasma concentrates. These therapies are expensive and sometimes stimulate the body to produce antibodies against the factors that inhibit the benefits of treatment. In these
situations, other clotting factors such as Factor VII and X may be used to treat patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The most prevalent form of the disease,
hemophilia A, is caused by a defect in the clotting Factor 8 gene. According to the National Hemophilia Foundation and the World Federation of Hemophilia, hemophilia A occurs in about one in every 5,000 male births in the United States, with
approximately 16,000 males currently affected. Defects in clotting Factor 9 gene lead to hemophilia B. Hemophilia B occurs in about one in every 25,000 male births in the United States, with approximately 4,000 males currently affected. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-525</FONT> &#151; Hemophilia A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-525,</FONT> a gene therapy product candidate utilizing an AAV carrying a clotting Factor
8 gene construct that is driven by our proprietary synthetic liver specific promoter. In 2016, we presented preclinical data demonstrating production of supraphysiological levels of human Factor VIII clotting protein, or hFVIII, in mice and <FONT
STYLE="white-space:nowrap">non-human</FONT> primates, or NHPs. In these dose-ranging preclinical studies, mean hFVIII levels of 5 &#151; 230% of normal were observed using AAV doses in the range of 6.00E+11 &#151; 6.00E+12 vg/kg, the most potent
dose response reported in NHPs for a human Factor 8 gene construct at the time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated a Phase 1/2 clinical trial, the
Alta Study, to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">SB-525</FONT> in adults with severe hemophilia A. The Alta Study is an open-label, ascending-dose study designed to enroll up
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to 20 adult subjects across six potential dose cohorts. In August 2017, we announced that the first subject was treated in our Alta Study. Currently, there are four patients dosed with <FONT
STYLE="white-space:nowrap">SB-525.</FONT> We expect to release preliminary data from the Alta Study in the third quarter of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT
STYLE="white-space:nowrap">SB-525</FONT> has been granted Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration, or FDA, as well as Orphan Medicinal Product designation by the European Medicines Agency, or EMA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-FIX</FONT> &#151; Hemophilia B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-FIX,</FONT> an <I>in vivo</I> genome editing product candidate, to treat hemophilia B.
Utilizing our ZFN genome editing technology, we are adding a new therapeutic copy of the Factor 9 gene precisely into the Albumin gene locus in liver cells, and using the strong endogenous Albumin promoter to drive expression of the newly inserted
gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for chronic infusions of replacement proteins or clotting factor products.
We have published data demonstrating the potential utility of this approach for several different monogenic disease applications in addition to hemophilia B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies of the Albumin genome editing approach have demonstrated that therapeutic levels of Factor IX clotting protein could be
generated in a dose-dependent manner in NHPs. There were no significant alterations in circulating Albumin levels. Studies in mice also demonstrated stable Factor IX production for over one year. Preclinical studies in wildtype mice have
demonstrated expression of therapeutic levels of human clotting Factor IX protein, or hFIX, from the liver and into the blood for the duration of the <FONT STYLE="white-space:nowrap">60-week</FONT> study. Additional preclinical studies in mouse
models of hemophilia B demonstrated expression of therapeutic levels of hFIX from the liver and into the blood, which resulted in the correction of the clotting defect in hemophilia B mice treated with a single dose of
<FONT STYLE="white-space:nowrap">SB-FIX.</FONT> <FONT STYLE="white-space:nowrap">SB-FIX</FONT> was also evaluated in preclinical NHP studies and demonstrated dose-dependent, therapeutic levels of hFIX expression, between <FONT
STYLE="white-space:nowrap">20-50%</FONT> of normal, in wildtype cynomolgus monkeys, after a single administration of <FONT STYLE="white-space:nowrap">SB-FIX.</FONT> Levels of hFIX were stable for up to three months in treated NHPs. Furthermore,
there was a strong dose-response correlation between the level of gene modification at the Albumin locus and the levels of hFIX measured in the blood. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2016, we initiated a Phase 1/2, open-label, ascending dose clinical trial, the FIXtendz Study, to evaluate safety and efficacy of <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> in adult males with severe hemophilia B. The FIXtendz Study is designed to enroll up to 12 subjects across three dose cohorts. In February 2018, the Medicines and Healthcare Products Regulatory Agency, or
MHRA, of the United Kingdom granted Clinical Trial Authorisation, or CTA, for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating <FONT STYLE="white-space:nowrap">SB-FIX</FONT> for hemophilia B. The CTA permits evaluation of <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> in both adults and adolescents. We expect to open clinical trial sites in the United Kingdom in the second half of 2018. Once preliminary safety has been demonstrated in the ongoing <FONT
STYLE="white-space:nowrap">SB-FIX</FONT> Phase 1/2 clinical trial in adults (18 years of older), we may begin enrolling adolescents (12&nbsp;&#150;&nbsp;17 years of age) into the study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-FIX</FONT> has been granted Orphan Drug and Fast Track designations by the FDA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lysosomal Storage Disorders </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">LSDs
are a heterogeneous group of rare inherited metabolic disorders including: MPS I, MPS II, Fabry disease, Gaucher disease and many others. These disorders are caused by defects in genes that encode proteins known as enzymes, which break down and
eliminate unwanted substances in cells. These enzymes are found in structures called lysosomes which act as recycling sites in cells, breaking down unwanted material into simple products. A defect in a lysosomal enzyme leads to the accumulation of
toxic levels of the substance that the enzyme would normally eliminate. These toxic levels may cause cell damage which can lead to serious health problems. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MPS I is caused by mutations in the gene encoding the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">alpha-L-iduronidase,</FONT></FONT> or IDUA, enzyme, resulting in a deficiency of IDUA enzyme, which is required for the degradation of the glycosaminoglycans, or GAGs, dermatan sulfate and heparin sulfate. The inability to
degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Depending on the severity of the mutations and degree of residual enzyme activity,
affected individuals may develop enlarged internal organs, joint stiffness, skeletal deformities, corneal clouding, hearing loss and cognition impairments. Three forms of MPS I, in order of increasing severity, include Scheie, Hurler-Scheie and
Hurler syndromes. According to the National MPS Society, one in 500,000 births in the United States will result in Scheie syndrome, one in 115,000 births in Hurler/Scheie, and one in 100,000 births results in Hurler syndrome. There are approximately
1,000 MPS I patients in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">MPS II is an <FONT STYLE="white-space:nowrap">X-linked</FONT> disorder primarily affecting
males and caused by mutations in the gene encoding the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">iduronate-2-sulfatase,</FONT></FONT> or IDS, enzyme. This results in a deficiency of IDS enzyme, which is required for the
degradation of GAGs. Similar to MPS I, the inability to degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Children with MPS II appear
normal at birth but begin showing symptoms of developmental delay by age&nbsp;2&nbsp;&#150;3&nbsp;years. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop delayed development,
enlarged internal organs, cardiovascular disorders, stunted growth and skeletal abnormalities and hearing loss. The disorder is progressive and symptoms range from mild (normal cognitive function) to severe (cognitively impaired). According to the
National MPS Society, one in 100,000 male births in the United States will result in MPS II. There are approximately 500 MPS II patients in the United&nbsp;States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Fabry disease is an <FONT STYLE="white-space:nowrap">X-linked</FONT> disorder primarily affecting males and caused by a mutation in the gene
encoding the alpha-galactosidase A, or <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A, enzyme, resulting in a deficiency of <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A enzyme, which is required for the degradation of the ganglioside
globotriaosylceramide, a particular type of fatty substance. The inability to degrade this fatty substance leads to its accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and
damage. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop progressive kidney damage, heart attack, stroke, gastrointestinal complications, corneal opacity, tinnitus and hearing loss.
Milder forms of the disorder present later in life and affect only the heart or kidneys. According to the National Institutes of Health U.S. National Library of Medicine, one in 40,000 to one in 60,000 male births in the United States will result in
Fabry disease. There are approximately 2,200 males with Fabry disease in the United States. This mutation can also occur in females, however is less common and the frequency is unknown. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are limited treatments currently available for MPS I, MPS II and Fabry disease. For individuals with MPS I, there are only two options:
hematopoietic stem cell transplantation, or HSCT, for those with the most severe form of the disease (Hurler) and enzyme replacement therapy, or ERT, for patients with the attenuated forms of the disease (Hurler-Scheie, Scheie). However, the
reported mortality rate after HSCT is approximately 15% and the survival rate with successful engraftment is 56%. Most patients with milder forms of the disease receive weekly ERT, usually in a doctor&#146;s office. These IDUA enzyme infusions take
on average four to six hours to administer. Weekly and <FONT STYLE="white-space:nowrap">bi-weekly</FONT> ERT infusions are the only available options for MPS II and Fabry disease, respectively. Because of the availability of few treatment options
that effectively and safely treat these diseases, there remains significant unmet medical need. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-913</FONT> &#151; MPS II </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-913,</FONT> an <I>in vivo </I>genome editing product candidate, to treat MPS II. Similar
to <FONT STYLE="white-space:nowrap">SB-318,</FONT> we are using our ZFN genome editing technology to add a new therapeutic copy of the IDS gene precisely into the <I>Albumin</I> gene locus in the genome of liver cells, using the strong endogenous
Albumin promoter to drive expression of the newly inserted gene. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical mouse model data demonstrated robust levels of IDS enzyme expression in the liver,
blood plasma and spleen of <FONT STYLE="white-space:nowrap">SB-913</FONT> treated mice, resulting in a <FONT STYLE="white-space:nowrap">100-fold</FONT> increase in IDS activity, with sustained elevated levels in the blood plasma over the course of
the entire study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDS enzyme from the liver into the circulation and additional secondary tissues, including the spleen, lung, muscle, heart and brain,
after a single intravenous administration of <FONT STYLE="white-space:nowrap">SB-913.</FONT> This resulted in the significant reduction of GAG biomarkers across all the tissues. Behavioral data from Barnes maze tests, collected at the end of the
four-month study demonstrated statistically significant preservation of cognitive learning and memory in mice treated with <FONT STYLE="white-space:nowrap">SB-913,</FONT> compared to untreated mice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the CHAMPIONS Study, to evaluate the safety and efficacy of <FONT
STYLE="white-space:nowrap">SB-913</FONT> in adult male subjects with attenuated MPS II, designed to enroll up to nine subjects across three ascending dose cohorts. In November 2017, we announced that the first subject had been treated in the
CHAMPIONS Study. In February 2018, we presented preliminary <FONT STYLE="white-space:nowrap">six-week</FONT> safety data from the first subject enrolled in the CHAMPIONS Study. The data demonstrated that the subject tolerated the infusion well. Mild
(Grade 1) adverse events related to the study drug were reported on the fourth day after dosing. These were dizziness, weakness and frequent urination, all of which resolved within one day without treatment. No other adverse events related to the
study drug have been observed. Liver function tests have remained within normal limits for the patient since the infusion. Currently, there are four patients dosed with <FONT STYLE="white-space:nowrap">SB-913.</FONT> We expect to present additional
safety and preliminary efficacy data from the CHAMPIONS Study in the third quarter of 2018. We submitted a CTA in the first half of 2018 to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical
trial. We expect to open clinical trial sites in the United Kingdom in the second half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-913</FONT> has been granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as
well as Orphan Medicinal Product designation by the EMA. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">SB-318</FONT> &#151; MPS I </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">SB-318,</FONT> an <I>in vivo</I> genome editing product candidate, to treat MPS I. Using the
same approach as our hemophilia B product candidate, <FONT STYLE="white-space:nowrap">SB-FIX,</FONT> we are adding a new therapeutic copy of the IDUA gene precisely into the <I>Albumin</I> gene locus in the genome of liver cells, using the strong
endogenous Albumin promoter to drive expression of the newly inserted gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for
chronic ERT infusions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical mouse model data demonstrated robust levels of IDUA enzyme expression in the liver, blood plasma and
spleen of <FONT STYLE="white-space:nowrap">SB-318</FONT> treated mice, resulting in a <FONT STYLE="white-space:nowrap">10-fold</FONT> increase in IDUA activity, with sustained elevated levels in the blood plasma over the course of the <FONT
STYLE="white-space:nowrap">two-month</FONT> study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDUA enzyme from the liver into the circulation and secondary tissues, including the spleen, lung,
muscle, heart and brain, after a single intravenous administration of <FONT STYLE="white-space:nowrap">SB-318.</FONT> This resulted in the significant reduction of GAG biomarkers in all of the tissues. Behavioral data from Barnes maze tests,
collected at the end of the four-month study, demonstrated statistically significant preservation of cognitive learning and memory in mice treated with <FONT STYLE="white-space:nowrap">SB-318,</FONT> compared to untreated mice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the EMPOWERS Study, to evaluate
<FONT STYLE="white-space:nowrap">SB-318</FONT> in adult subjects with attenuated MPS I. The EMPOWERS Study is designed to enroll up to nine subjects across three ascending dose cohorts. Based on the preliminary safety data from the CHAMPIONS Study
discussed above, in April 2018, we amended the protocol for the EMPOWERS Study so that the patients would initiate treatment in the study at the <FONT STYLE="white-space:nowrap">mid-dose</FONT> level. We expect to present preliminary safety and
efficacy </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
data from the EMPOWERS Study in 2018. We submitted a CTA to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical trial. We expect to open
clinical trial sites in the United Kingdom in the second half of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">SB-318</FONT> MPS I has been
granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Medicinal Product designation by the EMA. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ST-920</FONT> &#151; Fabry Disease </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ST-920</FONT> for Fabry disease. <FONT STYLE="white-space:nowrap">ST-920</FONT> is a gene
therapy product candidate utilizing an AAV, carrying a galactosidase alpha, or GLA, gene construct, coding for the <FONT STYLE="white-space:nowrap">alpha-Gal</FONT> A enzyme, driven by our proprietary synthetic liver specific promoter. We are
currently conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies for <FONT STYLE="white-space:nowrap">ST-920</FONT> and expect to file an IND application with the FDA in 2018. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Hemoglobinopathies: Beta-thalassemia and Sickle Cell Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations in the gene encoding beta-globin, the oxygen carrying protein of red blood cells, lead to hemoglobinopathies such as beta-thalassemia
and sickle cell disease, or SCD. Both diseases manifest in the months after birth, when patients switch from producing functional fetal gamma-globin to a mutant form of adult beta-globin, which results in their condition. Naturally occurring
increased levels of fetal hemoglobin have been shown to reduce the severity of both beta-thalassemia and SCD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beta-thalassemia is a rare
disorder that results in greatly impaired production of healthy red blood cells despite bone marrow over activity, leading to life-threatening anemia, enlarged spleen, liver and heart, and bone abnormalities. We are focused on Beta-thalassemia major
which is a severe form of thalassemia that requires regular, often monthly, blood transfusions and subsequent iron-chelation therapy to treat iron overload. The Centers for Disease Control and Prevention, or CDC, estimates that 1,000 people have
beta-thalassemia major in the United States, and an unknown number carry the genetic trait and can pass it on to their children. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In SCD,
the mutation causes the red blood cells to form an abnormal sickle or crescent shape. The cells are fragile and deliver less oxygen to the body&#146;s tissues. They can also get stuck more easily in small blood vessels and break into pieces that can
interrupt healthy blood flow which further decrease the amount of oxygen flowing to body tissues. Almost all patients with SCD experience these painful vaso-occlusive crises, which can last from hours to days and may cause irreversible organ damage.
Current standard of care is to manage and control symptoms, and to limit the number of crises. Treatments include administration of hydroxyurea, blood transfusions, iron-chelation therapy, pain medications and antibiotics. The CDC estimates that
there are 90,000 to 100,000 Americans living with SCD, which occurs in approximately one out of every 365 African-American births and one out of every 16,300 Hispanic-American births. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><B><FONT STYLE="white-space:nowrap">ST-400</FONT> &#151; Beta-thalassemia; <FONT STYLE="white-space:nowrap">BIVV-003</FONT> &#151; SCD
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing <FONT STYLE="white-space:nowrap">ST-400</FONT> for the treatment of beta-thalassemia and our collaboration partner,
Bioverativ, is developing <FONT STYLE="white-space:nowrap">BIVV-003</FONT> for the treatment of SCD. Both <FONT STYLE="white-space:nowrap">ST-400</FONT> and <FONT STYLE="white-space:nowrap">BIVV-003</FONT> are genome-edited cell therapies that use
our ZFN genome editing technology to modify a patient&#146;s own, or autologous, hematopoietic stem/progenitor cells, or HSPCs, to produce functional red blood cells using fetal hemoglobin. Our genome editing technology can be used in HSPCs to
precisely disrupt regulatory sequences that control the expression of key transcriptional regulators, such as the BCL11A erythroid enhancer sequence, to reverse the switch from expression of the mutant adult beta-globin back to the production of
functional fetal gamma-globin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current standard of care for beta-thalassemia includes chronic blood transfusions, while the standard
of care for SCD is a bone marrow transplant, or BMT, of HSPCs from a &#147;matched&#148; related donor, or an allogeneic </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
BMT. However, these therapies are limited due to the risk of iron overload with blood transfusions, requiring subsequent iron chelation therapy, and the scarcity of matched donors and the
significant risk of Graft versus Host Disease, or GvHD, with BMTs after transplantation of the foreign cells. By performing genome editing in HSPCs that are isolated from and subsequently returned to the same patient (i.e., an autologous HSPC
transplant), our approach has the potential to address these limitations. The goal of this approach is to develop a <FONT STYLE="white-space:nowrap">one-time</FONT> long-lasting treatment for beta-thalassemia and SCD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical data from clinical-scale in vitro studies have demonstrated that <FONT STYLE="white-space:nowrap">ST-400</FONT> and <FONT
STYLE="white-space:nowrap">BIVV-003</FONT> can be manufactured by reproducible, high-level, <FONT STYLE="white-space:nowrap">ZFN-mediated</FONT> modification in HSPCs mobilized in peripheral blood at clinical production scale (&gt;108 cells), with
an <FONT STYLE="white-space:nowrap">on-target</FONT> modification efficiency of greater than 80%. Furthermore, erythroid differentiation of enhancer targeted cells showed modification of both BCL11A erythroid enhancer alleles in more than 50% of the
erythroid colonies and resulted in a greater than four-fold increase in gamma globin mRNA and protein production, compared to controls. Specificity studies of <FONT STYLE="white-space:nowrap">ST-400</FONT> and
<FONT STYLE="white-space:nowrap">BIVV-003</FONT> revealed no detectable <FONT STYLE="white-space:nowrap">off-target</FONT> activity using <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">state-of-the</FONT></FONT> art, unbiased,
highly sensitive oligo-capture assays. Preclinical data from <I>in vivo</I> studies in immune-deficient mice demonstrated robust long-term (19 weeks) engraftment and that targeted gene modification was maintained through multi-lineage
differentiation in the bone marrow and peripheral blood. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our IND for <FONT STYLE="white-space:nowrap">ST-400</FONT> was cleared by the
FDA in September 2017, and we have designed an open-label, single arm Phase 1/2 clinical trial to evaluate the safety and efficacy of <FONT STYLE="white-space:nowrap">ST-400</FONT> in up to six adult subjects with beta-thalassemia. In March 2018, we
initiated the first clinical site for this beta-thalassemia study and we expect to begin enrolling patients in the first half of 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Bioverativ is our partner for <FONT STYLE="white-space:nowrap">ST-400</FONT> and is responsible for the clinical development of <FONT
STYLE="white-space:nowrap">BIVV-003</FONT> for SCD. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I><FONT STYLE="white-space:nowrap">CNS-Tauopathies</FONT> </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are using our <FONT STYLE="white-space:nowrap">ZFP-TF</FONT> gene regulation platform to develop potential gene therapies for tauopathy
disorders, including Alzheimer&#146;s disease and other neurodegenerative diseases. We believe a reduction in tau protein levels can help reduce intracellular tau protein aggregation and the formation of neurofibrillary tangles in neurons,
potentially ameliorating or reversing disease progression.&nbsp;We believe this approach may have a significant advantage compared to monoclonal antibody-based approaches to Alzheimer&#146;s disease and other tauopathy disorders because it is
designed to selectively down-regulate the <I>tau </I>gene in neurons with the goal of reducing all forms of the tau protein globally across the CNS. In contrast, monoclonal antibody-based approaches are limited in that they can only bind to certain
forms of tau proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Preclinical studies in wildtype mice demonstrated that a single administration of <I>tau-</I>targeting <FONT
STYLE="white-space:nowrap">ZFP-TFs</FONT> resulted in up to 70% reduction of tau mRNA and protein expression across the entire CNS, as well as sustained and well-tolerated <FONT STYLE="white-space:nowrap">ZFP-TF</FONT> expression with minimal impact
on inflammatory markers. Additional preclinical studies in amyloid mouse models of Alzheimer&#146;s disease demonstrated up to 80% reduction of tau protein levels in the brain and cerebrospinal fluid, as well as significantly reduced neuritic
dystrophy after a single administration of <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> in mice with established disease pathology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We
are currently conducting preclinical studies in NHPs to evaluate our <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> in larger mammalian species. We intend to seek a partner with disease area expertise for the clinical development and
commercialization of this program. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>C9ORF72&#150;linked ALS/FTLD </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2017, we entered into a research collaboration and license agreement with Pfizer to develop and commercialize gene therapy products
that use our ZFP TFs to treat ALS and FTLD linked to mutations of the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
C9ORF72 gene. ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involve hundreds of additional repetitions of a six base pair
sequence of DNA. This ultimately leads to the deterioration of motor neurons, in the case of ALS, or neurons in the frontal and temporal lobes, in the case of FTLD. Currently, there are no cures to halt or reverse the progression of ALS or FTLD. The
C9ORF72 mutation is linked to approximately <FONT STYLE="white-space:nowrap">one-third</FONT> of cases of familial ALS. We and Pfizer plan to investigate allele-specific <FONT STYLE="white-space:nowrap">ZFP-TFs</FONT> with the potential to
differentiate the mutant C9ORF72 allele from the wildtype allele and to specifically down-regulate expression of the mutant form of the gene. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Huntington&#146;s Disease </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Huntington&#146;s disease is an inherited, progressive neurologic disease for which there is no treatment or cure. The disease is caused by a
particular type of mutation in a single gene, the HTT gene. Most patients inherit one normal and one defective or mutant copy of the HTT gene, which causes Huntington&#146;s disease. The mutation is characterized by expansion of a repeated stretch
of DNA sequence within the gene called a &#147;CAG repeat.&#148; A normal copy of the HTT gene usually has 10 to 29 of these CAG repeats but a defective copy has many more &#151; generally greater than 39 repeats. While the protein produced by the
normal copy of the gene appears to be essential for development (mice lacking the gene do not survive to birth), the product of the mutated gene is damaging to cells. Symptoms, which include deterioration of muscle control, cognition and memory,
usually develop between 35 and 44 years of age. It is known that the greater the number of CAG repeats, the earlier the onset. Huntington&#146;s disease is usually fatal within 15 to 20 years after the onset of symptoms. The disease has a high
prevalence for an inherited disorder. According to the Huntington&#146;s Disease Society of America, approximately 30,000 people in the United States have Huntington&#146;s disease. In addition, it is estimated that approximately 200,000 people in
the United States are at risk of developing the disease. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research in animal models of the disease has shown that lowering the levels of
the mutant HTT protein can prevent, or even reverse, disease progression. However, to date most <FONT STYLE="white-space:nowrap">&#147;HTT-lowering&#148;</FONT> methods decrease levels of both the normal and mutant forms of HTT, raising potential
safety concerns given the importance of normal HTT protein. In collaboration with Shire, we are developing ZFP TFs that can selectively repress the expression of the mutant disease-causing form of HTT while leaving expression levels of the normal
gene unchanged. Preclinical studies in animal models of the disease are ongoing and Shire is responsible for all clinical development activities including filing the IND application. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We previously announced a data security incident involving the compromise of a senior executive&#146;s company email account. While we are
continuing to analyze the effects of the incident, along with the appropriate remediation of our information technology systems, at this time we do not believe that our ongoing clinical trials or any data from these trials have been compromised,
particularly because we restrict the receipt of data from our clinical trials to a very limited number of employees. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>New ZFN Architectures </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2017, our scientists reported on platform advancements that substantially enhanced the precision, efficiency and specificity of ZFNs for
therapeutic genome editing. We believe these advances enable rapid development of ZFNs to target chosen genomic sites with high levels of targeted modification and with no detectable <FONT STYLE="white-space:nowrap">off-target</FONT> activity. These
advances include the development of new linkers that enable base skipping between adjacent zinc finger modules as well as a reconfiguring of the ZFN architecture to allow optional placement of the Fok1 nuclease domain at either the carboxy terminal
or the amino terminal end. The enhancements also include the identification of key amino acid substitutions that can be used to tune biochemical properties and remove <FONT STYLE="white-space:nowrap">non-specific</FONT> binding contacts between the
ZFN and the DNA backbone. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Advancements in T Cell Editing Capabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2018, we presented preclinical data demonstrating our ability to accomplish highly efficient multiplex genome editing of T&nbsp;cells.
Efficient multiplex editing, the ability to make multiple genetic changes in a single step, enables simultaneous disruption of certain genes to prevent the body from rejecting the treatment and integration of new genes to equip the modified T cells
with targeted antitumor functions. In the presented data, we described a T cell with four edits achieved in a single step. The four simultaneous edits included triple knockout of TCR (93% efficiency), b2 microglobulin, or B2M, (96% efficiency),
CISH, a checkpoint gene (93% efficiency), and targeted insertion of green fluorescent protein, or GFP, (91% efficiency), resulting in 76% of the modified T cells with all four edits. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our T cell engineering capabilities have advanced rapidly in the last two years with improvements in our ZFN design capabilities. These novel
architectural enhancements have resulted in a <FONT STYLE="white-space:nowrap">300-fold</FONT> increase in potential design options for a given genetic sequence, yielding higher <FONT STYLE="white-space:nowrap">on-target</FONT> modification activity
in preclinical testing, with <I>ex vivo</I> editing efficiencies now reaching as high as 99.5%, and <FONT STYLE="white-space:nowrap">off-target</FONT> cleavage consistently below the level of detection. We believe these improvements potentially
allow for the use of substantially reduced doses of mRNA and AAV, enabling a highly efficient gene editing process that maintains T cell phenotypes, functions and proliferative capacity during <I>ex vivo</I> cell expansion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Exhibit
99.1 contains forward-looking statements regarding our current expectations. These forward looking statements include, without limitation, references to: the potential value and therapeutic use of our technology programs; our intent to partner with
other companies to advance the development and commercialization of our programs; anticipated activities under our collaborations and the scope thereof; the anticipated initiation, enrollment, scope and rate of progress of, and data availability and
other milestones related to, our preclinical studies and clinical trials and those of our collaborators, as well as the anticipated timing thereof; anticipated regulatory submissions and the timing thereof; our belief as to the criticality of our
intellectual property position; our beliefs as to the advancements in our T cell editing capabilities; and other statements that are not historical fact. These statements are not guarantees of future performance and are subject to certain risks,
uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ include, but are not limited to, our dependence on the success of the clinical trials of our lead programs; uncertainties related to the
initiation, enrollment and completion of clinical trials and the timing of data availability; whether clinical trial results will validate and support the safety and efficacy of our product candidates; our ability to maintain our collaborative
relationships and our reliance on collaborators and other third parties to meet their obligations; our ability to establish additional collaborations or strategic partnerships; our ability to obtain or protect intellectual property rights related to
our product candidates; technological challenges we may encounter; the lengthy and uncertain regulatory approval process; our ability to develop commercially viable products; technological developments by our competitors; and other risks and
uncertainties affecting Sangamo and its development programs. Actual results may differ from those projected in forward-looking statements due to risks and uncertainties that exist in our operations and business environments. These risks and
uncertainties are described more fully under the heading &#147;Risk Factors&#148; contained in Exhibit 99.1 to our Current Report on Form 8-K, filed with the Securities and Exchange Commission on April 17, 2018. Forward-looking statements contained
in this Exhibit 99.1 are made as of the date hereof, and Sangamo undertakes no duty to update such information except as required under applicable law. </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g575619g13d40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g575619g13d40.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1MX4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $4< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' (   (  !P"4  15&AO;6%S(%1U8V-I87)O;F4 .$))300E       0:7FC
M:U"JZP94JP\.6!BB"#A"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!JN3^
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 \     !  $#P     $  3A"
M24T$)@      #@             _@   .$))300-       $    >#A"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))300>       $     #A"24T$&@
M   #-0    8              IT   5*          $
M         0             %2@   IT                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   IT     4F=H=&QO;F<   5*    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   *=     %)G:'1L;VYG   %2@    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M^L^]]?:CO_G,W_JAKCZ@/$3U.HQS-5NO'[O4!X((_P 6]^XG]O6:SH&&-?\
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M>]SOL[J[@:P?TUK6@.@[?I,/TO[*2&QN?^[^*A:X[#N;(TX.LS[?^DBH=_\
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M:USO^BJ_[*#:BT86,2X-+AO<!N#BZ?4]-SW;/_!%K))*<@]+XCI^+$D$&QW
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M;2R[<=HJ<"-L"/I;O=])1^R=6$1U!C@#/NH:26_N^RRO_.VJSE":SM( @\Q
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M &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %
M: !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !3DU- "H
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M   "G0         & 0,  P    $ !@   1H !0    $   $^ 1L !0    $
M  %& 2@  P    $  @   @$ !     $   %. @( !     $
M $@    !    2     $X0DE- _T       @          /_A 5!-30 J
M"  ( 1(  P    $      1H !0    $   !N 1L !0    $   !V 2@  P
M  $  @   3$  @   !X   !^ 3(  @   !0   "< 3L  @   !(   "PAVD
M!     $   #$    \    \     !   #P     %!9&]B92!0:&]T;W-H;W @
M0U,V("A7:6YD;W=S*0 R,#$X.C T.C(T(# Q.C4X.C Y %1H;VUA<R!4=6-C
M:6%R;VYE      .@ 0 #     ?__  "@ @ $     0  !4J@ P $     0
M IT         !@$#  ,    !  8   $:  4    !   !/@$;  4    !   !
M1@$H  ,    !  (   (!  0    !   !3@("  0    !              /
M     0   \     !_^% &FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\
M/#]X<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C
M>FMC.60B/SX\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(B!X
M.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ-#4V-C$L(#(P
M,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z4D1&('AM;&YS
M.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X
M+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @
M(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+R(^"B @(" @(" @(#QX;7 Z0W)E871E1&%T93XR,#$X+3 T+3(T5# S
M.C U.C4U*S U.C,P/"]X;7 Z0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#
M<F5A=&]R5&]O;#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C Q."TP
M-"TR-%0P,3HU.#HP.2TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @
M(#QX;7 Z365T861A=&%$871E/C(P,3@M,#0M,C14,#$Z-3@Z,#DM,#<Z,# \
M+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@
M(" @(" @(" \<&1F.E!R;V1U8V5R/DUI8W)O<V]F=,*N($]F9FEC92!7;W)D
M(#(P,#<\+W!D9CI0<F]D=6-E<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^
M"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @
M(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ
M+R(^"B @(" @(" @(#QD8SIC<F5A=&]R/@H@(" @(" @(" @(" \<F1F.E-E
M<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y4:&]M87,@5'5C8VEA<F]N93PO
M<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO9&,Z
M8W)E871O<CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF
M;W)M870^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W1%=G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C945V96YT(R(*(" @(" @(" @(" @>&UL;G,Z<W12968]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E
M9B,B/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C=!-C$S
M.#<P.4,T-T4X,3$Y,$9!1D)%,38R.31%1CE#/"]X;7!-33I);G-T86YC94E$
M/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C(S,$,R1C$Y
M,D$T-T4X,3%!-S0T04%#.3,S-4-&031&/"]X;7!-33I$;V-U;65N=$E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,C,P
M0S)&,3DR030W13@Q,4$W-#1!04,Y,S,U0T9!-$8\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @
M(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C(S,$,R1C$Y,D$T-T4X,3%!-S0T
M04%#.3,S-4-&031&/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3(T5# S.C Y.C(P*S U.C,P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V
M=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$
M/GAM<"YI:60Z-SDV,3,X-S Y0S0W13@Q,3DP1D%&0D4Q-C(Y-$5&.4,\+W-T
M179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N
M/C(P,3@M,#0M,C14,#$Z-3@Z,#DM,#<Z,# \+W-T179T.G=H96X^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O
M<VAO<"!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @
M(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^8V]N=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IP87)A;65T97)S/F9R;VT@87!P;&EC
M871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V
M=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^9&5R:79E9#PO<W1%=G0Z
M86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYC
M;VYV97)T960@9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P
M('1O(&EM86=E+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C
M=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C=!-C$S.#<P.4,T-T4X,3$Y,$9!
M1D)%,38R.31%1CE#/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z=VAE;CXR,#$X+3 T+3(T5# Q.C4X.C Y+3 W.C P/"]S
M=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!
M9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F
M='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^
M+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y
M/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N
M:6ED.C<Y-C$S.#<P.4,T-T4X,3$Y,$9!1D)%,38R.31%1CE#/"]S=%)E9CII
M;G-T86YC94E$/@H@(" @(" @(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N
M9&ED.C(S,$,R1C$Y,D$T-T4X,3%!-S0T04%#.3,S-4-&031&/"]S=%)E9CID
M;V-U;65N=$E$/@H@(" @(" @(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N
M=$E$/GAM<"YD:60Z,C,P0S)&,3DR030W13@Q,4$W-#1!04,Y,S,U0T9!-$8\
M+W-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$
M97)I=F5D1G)O;3X*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @(#QR
M9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM;&YS
M.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O,2XP
M+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO
M<#I#;VQO<DUO9&4^"B @(" @(" @(#QP:&]T;W-H;W Z1&]C=6UE;G1!;F-E
M<W1O<G,^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/GAM<"YD:60Z,C,P0S)&,3DR030W13@Q,4$W-#1!04,Y,S,U0T9!
M-$8\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \
M+W!H;W1O<VAO<#I$;V-U;65N=$%N8V5S=&]R<SX*(" @(" @/"]R9&8Z1&5S
M8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE=&$^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_
MVP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0'_P  1" $L F # 1$  A$! Q$!_\0 'P !  $$ P$! 0            $%
M!@<( @0) PH+_\0 =Q    8! @,#!04-$0H)" 4- 0(#! 4&!P 1"!(A%#%!
M"1,5%E$7&2)"81@:)C(V5%565UAQ@9<C)2<S-#4W1$92D9.6H=76\"0H.$5'
M4V*8L=(*0TAXE)7!U-=E9F=WAM'A\7)U=H>VM[@Y9'2"A::GQX.2QO_$ !T!
M 0 !!0$! 0             ! @,$!08'" G_Q !P$0 ! P(#! ,("0X)!P@'
M! L! @,$ !$%$B$&$S%!!U%A%!46(G&!D? 7&#)25J&QT=,((R0E-5-459.4
ME<'5X28T-D)%8I+4\3-#1$9EEM(G9')T=8*$A6-V@Z*EM<5'9J2TXC=7<X:C
MIK*SPL3_V@ , P$  A$#$0 _ +@\J;Q_<;&*?* \36/<;<4&9Z31JO=HUC7:
MK7+O+1L)#,U:A6GAVT>P06*BV2.Z<N7!B)@ "HLH?;<PCKZ6V-V9V>F[+X1*
MEX/A\B2]'4IUYZ,A;CB@^\FZED$J-@E.O("O!-JMH,<B;0XG'C8G-8CM/I2V
MTT^I*$ LLFR4BP N5$\>))Y7T #RH/E#^G]^5Q ]1Z_HC3G3K[ <;;;?C\1'
MPUU'@=LKRP##-!?^*-Z\.SM\GF%SSOA5M'^.9Y-[ =TKTXVOP]!UYDWX<A\J
M!Y1#??YLGB  -NH>Z-.;A\O1Q^#_ -P[[A V/V5YX!AGYHU\U^O]UJJ.U&T9
MX8U/_.%CAIH->?KKI'OH/E$.@CQD\073OVR+.!OUVZ?W1T#QVZ#X>P-/ [97
M\087YXC>F@(X)\O+YZ@;4[1V^[.('_Q"]3K_ %K6\GF/*@>5!\H>/?QE<06P
MCTVR).]P[#X+]?';KOUZ=VG@=LKRP#"]!8WBMWY]8X]=NH7MPH-J=H^>-8AJ
M;Z2%VUUT/FT!MH3:]J@?*@^4/#_EE<07<.P^Z+.=1 >O[9WV ._Y>X>_3P.V
M6M]P,+/#_16].SA;7XM;T\*=HOQSB'#\(<L3U\22/);D>>L^^@>40#;^_*X@
M3;_^D6=^7_\ 6 VV_!\78=MQ'3P/V6_$&%\/P1KYO6^G50[4;1\._.(7)X]T
M+Z_*;:<..G$"U1[Z#Y0\=_[\KB"#;?NR+.B(#U'KNXVZ!^/Y/'4^!VRW+ ,+
M/EB-C2]NKF?7B*CPJVBN;XSB M_SAPFYUZR-!?LY<!>LNX-XW_*4Y\R;6<3U
MGCMRE6K-<7K:(KCB[Y8MD1#2,X^<MV49")O8UA,JIR,JZ<D09@NU(T$P"9=V
MW*',.!B6SNR.&1'IKNS<-YEA*G'1&A,..(:2"M;F52D H0E)*K$JY!)K-@8[
MM-B,IJ(UCTIIU\I0TI^4ZE"G%%*4HNA"U9EE0 ND)X$D UE*]9P\L33DJ1(P
M_%%Q#92K&1FBCJGW+%-WOUKJ\NHC/WJO'CRR"L5%KMI+M&.;8_[&[9MSA#QB
MLH82MTUQ1PXV&["2#(2O!L*AO1%!,B/,CQ6'FP6HSN8HSK!3:4RG,%'ZXL(M
M<B^6_.VR9#"D8IB$MJ2DEE^(](=;40X^WES%""%$QWE $)\1&:_&UEM.)ORT
M3Y=JV:94XUW#EX:<(T:)/;X9VY-69@*]8 1:^9\^H:)L!TX)\4J8^9F%F\8;
M^[5T4#Y!P?H_2%%4+9X !O,2F, DO-[UHW!( 6S=Q.NK84L: FK Q3;91 3*
MQLDES* 7B5;IPMN  @7+;ED*XV60DBYM7!+B?\L\X4KR3?*_&NN>V17IRM^8
M=W]4)N(%A$2I9&,%-N8';52.L$$[163,(+(3429(#^D68K2<&V &\O"V=&Y<
MW;UQ%NVO,X@H7KXI"VG$D$:%M8/N%V=\]M3D EXV2ZWG;L7_ !TY4+"DZ&Z2
MEQL@CB%I(OG37=I_$IY9:\C,C YSXL!;U^H'O<N^DKA9(ADSJX58]U:R(NI)
M9LFN>5JY!F89DV%=[+LA*M'-W"?4*'\(V"C9-[AV!@NO]S-A##*U*>WPCE&5
M 41D>^MN*("6U:+4#I1C$]M)&<MS\6RH9[H4I;KB$I9+6^2LJ41?.U9QL DN
M)OE!J@9-XP/*V8D]*N[GQ(<5$?78RVRU)3N:MDOK&J2E@AI"7BW;*-DYAC%G
M5.9[ 3B""3ALU=*+0\J@+8CB-?HM[L3 MAYV[3'PG!E/+81(,<,QE/(:<0VM
M*E(0I0ME=;)(44C.@@Y5H)HE8QM=#WBG\2Q5+:7E,![>OAI3J%+2I"5+0D@E
M3:P+I23E4+!256R/DG-GEF<82<)$RG$AQ&61W-8JC\PK&HV1+';$*[47<PM7
M7J5I6C]RP4Y7["D6 L<2[ %HN7<LV9CG4>MO.8L3#M@9B''$83A+*6YJH $F
M*TP77TMAT%D*'UQMUHEUI8N%(2HV\0UDRINVL12$*Q+$72N*)A+$A;J6V2LM
M$.Y=6UMN -NI(NE9 OXPK',QQ:>6,KS>TNYW,O&;#M:1'LY>X.I&3O31O6HN
M0%QV1_,*.$4R,FJP-'@>?6,4B9F;SSAB"U<>:RF\#V#=4REO#]GW%/J4AE*4
MQBIY:0G,EO*3F4,P-AJ0I-KYA6,O%MLVPZ7)F--AE(6\I2WLK259K%5^ (2=
M> L3I8UAGWT'RAX[_P!^5Q!;AT_9%G1Z[?(XZ#T$>O\ !XAG^!^ROX@PS\T:
MM\FOKK6%X4[1DV&,XAH+F\E7"W83Y].&M/?0?*']?[\KB"'\&19T/'Y7 C_/
MX[[=-BQX'[+?B#"_S1KCZ/G/IIX4[1B_VYQ \3_&%Z=G$Z^2P/$]=0'E0/*(
M=_S97$%M\N19SQWZ_JC^P_P:D['[*\L PL?^%;_X1Y^/HH-J=H_QSB!'_P"_
M7S\IY<K#@>1%/?0?*'@.WS97$#X=?=%G?$-^\7&VW< #XB.WMU/@;LN?Z PO
MM^Q&^NW)/Q>>AVJVB']-3R3P^R5VX=IX=O,]52/E0?*'AO\ WY7$#TW ?T19
MSP .OZ?L @ @/X>;O -1X';+:?:###P/\4;[>KE?3YM+O"G:+7[<XAU?QE?4
M.?)0'5VZ\2(]] \H>'_++X@AZ^&19SH'C^V-OD#O\/EU/@?LK?[@87S-NY6[
M<+^]\O,:]7"H\*=H@!?&L1N2.$A=^!Y::<#:Q[.-ZD/*@^4/$>G&5Q CMWA[
MHTX'4>[N<_@#P_!XZ'8[94?T!AHUYQ&N'HU/G\]3X4[1DZ8U.Y7^R'!J0;<[
M6OY#\=3[Z!Y0_?\ PRN(( ]ONBS@AW^ BXV'8/P#W[]VVH\#MEM?M!A?+_1&
M_7SZZVX:4\*-H_QUB&NO\87;C< :GB -/^E>XXWC9?*;^4%;P./%D.,;/)%G
MM5D7+TZ-]E4%%G)+W<F:9W:J;GSKM8&;1LD1=R +)MDD&Q/[G;(B-AK8_9@N
M2KX!AI"7DI3]C-D =S1U:>+XHS+)*1H3<G51%9#NT^T(;C$8S/!4RHJL^H%1
M$AY.MS<G*D *(%A8<A:S \J%Y0_;KQE<0/>'4,B3O4/^D;A\FWX]@'?5_P #
MME;_ ' PSA^"M=7DL?+6.-J=HP/NSB!\LA=^-O*.P:DWOPO4>^@^4/[_ )LO
MB"Z^S(LX'</L[0/>.X;;]/\ ;/@=LL/]7\,-CP[E;Y\-;:_%YQP>%.T1U[]8
M@+@G20OEV:V]/9QK9_AHXCO*N\54E;(W&_&MEIBI3F]:7E5;/DZ\H)JJV^P-
MZO M6:5?A[&\45<S#E%%99=JWCV*1A<OGC9N10X:;%\)V*P5#"I>ST$B070W
MNH<<D!AHO.J475M) #8N+$J4;)2E2CKM,,Q+:W%5/"-C<H%@-%>\DOBY>=#3
M82&T.DDKT-P$I&JE)'"C.^)+RSR$SZ";YBXQ99TK-6>"CWD%.7.9B9I]3W\A
M&6 \)+QQ'$=*L6;N*D"D?LG"C-R1JJ=JJJ0AA"M.$; %L.F!@*$[MIQ276X[
M:VTO)2MO>MK(4A2DK2<J@%>, >-JI5B>VH6IL3,84=XXVE2%O+0M;*U(<W:T
MC*M *3XR3ETNFXUJCQO%;Y9.8/7TXS+_ !IOE+4>43KQ&[V^G/,'@E%49A-D
M (?FRD>JBJDY .42J$,3J8!*-Y6"; HWN>!L^G<A)<N(MF]X 6RJZM L&Z;\
MB#Y+2<6VT7NPB9C2B\2&[%\Y\EPL) YI(\:UB3\?T#BI\LH+(9'W7^,\L>6N
MJVY1X,C>_-)5=#M8JSZH^8$48E,L?(J&>' J8I1LB<HF+'O#(T]Y=@2K*(.
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M.O&N=&RNT8!M@T\<;?6%?K)X]NM!\EGY13<1^8XSP'=W4>1[^\?P#X;]0Z>
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MOF5IRYW-B.K+4^]9^44WW^8WSQOW]*-(=-^_O#KN/7PZ[  ;B.SPRV5X=_\
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M_DT:VJW2F:7)V%\K+2KM.-B14F9EB>O0JY$F3-)\DHCYA=PB9!QNGNCO W7
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M_"VSNT)Y7XC#.K7L!ZJY!Y0SAZ$>8,M,^3G'_)+?-P+\$0*)O2NP&V _PA*
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M34IV2V_9VO\ </[EY#OY]P'ZK/!/X AXF^'T#X&E-?4?OH#2V^,[7^\.ZKR
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M A^A0+T^%L&X!W;FUZX=KME-?X2[/VZN_6'C0#4W,G51/(:\>I-OE4=%72>
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M :?ZG[0ZZ6OE.'V-KV&NB@-=*@,#9RVV]Q7+(;!L&V.;=RB(@( (_G/N E$
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M*1O/%0."O(0Q3Z?%>A;9*$_@S;+^-%.(8NB ^%S(I4&58?B$J[?V&,KF\BM
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M&3W7>Z\<V?@8I+2E3>+LI#(D27$QTE)4VV$I6XX05UACWT?B0YA_.S&7+_\
M9F8$?X LX .VPCN @ [@'3<!#ICT#[&6'V1CM^%N[8H%^(L3 X&]K6)%KZ\#
MYQ[=WI>N?M=L1;E]IL5)[188[K:Q.8$)-[#C< \J/Q(&[HW&703 /T-2_3;Q
MW]9P  W PB(AL!?$=M]#T#;&?A&._P TC[-BZ@\K" 2>('7STO:@^K=Z7B/N
M?L1<9@?M/B=A;@;]_P 6X%6HME\A- \J/Q(;[&C<9;]1Z5F8[@W$0 /67<3
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MQ&29'=(QK#P X)Y;W1CJR[LJWB@O*GXAY(U^&^V>FG4!W_0W6ZB( &_U<>P
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M</EQM/5;\5>NG50_4%2K$#I28 -C_(UPZW))_E0.-SIZ;U(>2.D W_1Z9]1
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M-76XAT\-SG<*<&S#C0PW$T8B4G& LOY84V)NK][$Y+]U[S/9=MWER>-F3T>
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MJ%S"JYRED-RHRQ4Z>L3N+K95Q:/"WRA-@=M15DQ%NX!NX<(%62\VKYIPNES
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M42E.LL<ZJABF.H<QQ,(V*^>GG5ONNON$%QYQ;KA"0D%;BBM1"4@)2"HFR4@
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MFV_:FVW?OY]+;;V_3:4J>UM.[M3??N_3D^_NV^FTI4=L:=_:FVW0?T]+N'J
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MZE[@V#8/#8-N[2E3ZH5+O]5Z[N.XB/H2-Z\V_-^UOC;CO[=QWU%AU"E I]2
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MU?:_1'T2[+;<;+OXSC+N+(EMXO+@I3!EL,,[EB-"=02AR(^HN%4A>96>Q 2
MD$$G6 /+E\7'W/.&+N$/V)I3N'D$0^K7N$4D^GB*:8C](7:O<I'OK>;R=7J*
M]1]KIL!^$;1?I&)^S:>_E\7'W/.&$.H#^Q-*=X!L _5MW@&X!MU -]NFIW"/
MZWQ=8[*CVN>P/X3M'^D(GF/W-]/ZJCW\OBX /V/.&'8 V_8EE #8# ?;ZMN[
MF #;>!@ >\ '3<)ZU>D?\-/:Z; ?A&T7D[XQ/3]S;_JI[^7Q<?<\X8>\1_8E
ME.\2\@C]6W>)?@B/[WH/34;A/6KXNL7UMZ^:GM<]@;_QC:+](Q.W_9OD]'GI
M[^5Q;]?T.^&'KW_H2RG7J8WVZ]?A'./X3F'O,.\[E'6KTCYJGVNFP'X1M%^D
M8GH^YOR]=/?R^+<1']#SAA'?F']B63W'FV V_P!&WQM@ WMZ;[[:;A%N?I'H
MX?JJ/:Y[ ?A&T7Z1B?LVGOY?%P(?L><,6W3?]":4^*!BEW^C7XH', >SF, =
MX[MRGK5Z1_PG]=3[7/8#\(VB_2,3]FT]_+XN-^N/.&'<-]OT)I3?J)#&'ZM?
M$Q""/M$A!'J4-FY1QNKES&OQ=M1[738#\(VBZONC$\Q^YW7IZZO?R^+C[GG#
M#T$!#]":4[P*!0'ZMN\"E*4/84H!W &FX0>:O2./]GT5/M=-@/O^T7Z1B?LV
MM@L!^5\XE,EM,[K6*@<.J9\;\/EWR;7O1F+WK4JECKLW4F4>E(@M;'/:(L4I
MQZ9PU2%LL=7S)R.D^0P*4EI(M;-J0#J.WLO>XX?%7-[1=!.Q6%+V>$9_'",4
MVD@85)WT^,HB+*8F..%K+ 1E>"F&\BE9@!F!2;W&OOOY?%Q]SSAA[Q']B:4[
MQ*4HC]6W>)2$*(]_*0H=Q0VJW*.M7ZODO\=='[7/8"W\8VBOU]\8G[-MZ]=!
M\N5Q<#T]SOAA[@+UQ+)C\$.<>7ZMN[=538.[\T/T^&;=N4=:K^;GYO1Z+T]K
MIL!^$;1=0^V,3C^C:GW\OBX$=_<\X8M]S#N.)I/?<_TX_5MWF$1$WB._7?3<
M(YE7I'7Y.>E/:Z; ??\ :+](Q.O3^C?6_HCW\OBX^YYPP]Q0_8FE.X@<I ^K
M;XI1$I? I=P#8!V%N4=:K\;7'S4]KGL#;^,;1?I&)^S34^_E\7'CCSAB^-_D
MFE.\QC'-^[7XQSF.;VF,81ZF$=-PCK5Z1\U3[7/8#3Z_M%^D8G[-I[^7Q<;[
MACSABZ"40'W)I3<!(!"E'?UV[R%33*4? $R &P%* -RC^MZ1^L?)YZCVN>P'
MX1M'^D8?I^YO/U[(]_*XM]MO<[X8=N7DY?<ED]N4=_@[>NNW+U'IW=1^73<)
MZU>D?-3VNFP)_P _M%^D8GH^YI\]K]FO"??S.+G??W/>&+FYA/O[DTIOS_!W
M-OZ[?3#RE^%W_!+UZ!J-RGK5\7'T?%QJ?:Y[ ?A&T0_\QB?LWY:CW\GBWVY?
M<[X8>7E G+[DLGMR%+R%)MZZ[<I2@!0+W 4-@#8-M-R@\"KR@CL[/7LJ/:Z;
M ?A&T1XW^V,3CU?<WMJ??S.+@=Q]SWAB$1$PB/N32G43\_.(CZ[=1/YQ3F'X
MWG#[[\YMYW*;#4WYZC7XM/FZZ>USV!YR-HN7#$8G[-_7\U;1<7?E:>(S!N5(
M6F4R@\/2T0_Q#A2\K'F\9/'SP)J^XRK%OFB)K-K2Q3*Q1EI5P6-0%$RK5H1!
M)1==1,5C4I921>ZN*AQ'(D<,O8/CKDMB^@_8W'\(D3IS^-AYK&L=P](CS8[;
M>XPW%94-@E*X+A*RRTC>+"LJUW4$H!M6K@^7+XMQ#8<=\,(@(& 0]R63$-C\
MXF 0]=>XXG/S;]#"8V^_,.\[A'6KXAZ-/UUUWM<]@/PC:+M^V,3]FU/OYG%S
MS<WN>\,7-S <#>Y-*;\Y1 Q3;^NVX& Q0$IM]P$ $!W --RCAXW#E;7XK=EC
MR]-1[7/8'\(VC\V(Q/UX;UZ^?G:H]_*XM@#E#'?#!MRB7;W)9/;D'DW+MZZ_
M2_ )N'=\ G3X(:;E',J\Y';V>0^NCVNFP'W_ &B_2,2W_P M_P :GW\OBXWW
M]SSABWYN??W)I3?FZAS;^NWTVQC!OW]1Z]1TW*>M5_*/F]/'Y+O:Z; V_C&T
M7Z1B?LWEY_(37I[Y)_RA68.-3B$NN+\OT7"#.M5[#,Y?(]2EX]5A9,9J*O&.
MZ^T27=2$[-(GCP8V-\<S<C5-07*+-4BY"H"FI0XV$)N"?=6UMPU^;C\5>4=,
M'11LQL)LW Q;!7<5<E2<;CX<X)TIA]KN=V!B,E12AJ(PH.;R(T K.4Y2L9;D
M%/Z!_4^H_:M7/C!^LD9\<ADS_M7XY#G(;]\0YBCN!A ;-?.-3ZGU+[5Z[WE'
M]9(SO(83D']3=Y3B)RC\4PB8-A$1TI4>I]1VV]5JYML8NWH2,VV.&QPV[+W'
M#H8.XP=!WTI4^J%3WW]5Z[ON!M_0D;OS!S[&_4W>'G%-A[_S0_[XVZE1ZGU+
M[5JYW<OZR1GTO,F?E_4O=SI)&V[N9-,W>0H@I4^I]2^U>N]!Y@_.2,Z#RB3?
M]3=_((DW[^41+W#MI2J)9&>-*? 2]IL\93X*O5^/<2LQ+R,7%-F,='L"]I6<
MN%CM@ I$?-@<A0W.94"%2*942%'*A0I>)3(T"!'=ES9CS<>-&825NO/.*"4(
M0D<22>)L$BZE$)!(P<3Q/#\&P^;BV*RV(&&X?'=ES9DE8;8CQV4E;CCBSP 2
M- +J4HA* I1 /F'FCBCR"]E)2*P)A_'473X*%>3-HR3:H%G:9Z&9%QT;);0C
M;'<8I&*M9F=JJ;<M?CI1V_%]*.V4-,)03SSR3?W;9OHPV68C,R-K<5F2,3E2
M41H6"8>4P8C[AQA.!.ES%WVGM['BSRKNQV.VSNX[;DF,J6T$J7\M[7=-NW<[
M$7X.P& 8?#P2'$7+Q':?%KXIB$=D[/':>.&, C/QQ&E3<+">X&9KLK?2WFX<
MQO#Y <;1XU9AX[N,ZK6M9.D7=&TQ:KMHA#R33ASID0QEG8L.WNHA.!E:$LZ[
M=$.CRD:X:@JZ.99D^<(+*MS^>-[GA?1)T6R(%YVSL:"\EMQ;[3FT<N2ZR@/%
MIM\RF<0"2T\@M/H59 "7D(4E*]*\5=Z:.F!&*)$;:N7B49QQM,=YO92%#9?4
M6 Z]&3$>PLJ#[#F^84B[BRJ.XX@K;LH;]>3 \I9:>)K*"?#[Q%X5JL5;9:!F
MI:@Y-KU%&OPUI<P#8TG,5Z=B73=Q'-YA2':OYAK(PSAI'N4XETT5BF[@$%EO
M&.EWH>P79/#%;1;,8@X["9D,LXCA,J2U*>AIDKW+,F,^@)=4QOU-LK:?2MQ)
M>0L/K3=(^DNA_I<QS:Z8G MJ(#:)CL=QZ!BL6,[%:EJ80IUZ/(85=E+P80X\
MEV.I#9#:FRPE7C'WR&GU(>^KUT>H&ZPD9W@4Y ']3=X$44( ]X%4.4.AC /S
MG7T54>I]2^U:N>(?K)&>)_.#^U?%3X8_Z?POINNE*GU/J0?N7KO?S?K)&?3<
MA$^;]3=_FTTR;]_(0A?I2@ *5'J?4?M6KG<!?UDC/I2F,8I?U+W%,8Q@#N Q
MC"'41TI5@Y3>4S%^.KAD)Q18*70J$(^G5(Q"-BF:ST&Q$C'03=*,%R(**@DB
M JF14 /-)[E'D+M<:;WKB&[Y<Z@FY%[7YVJAQ>[0I9%PD$VZ[5JI*\8V!4CQ
M;6O8KEYY_*.*SV.&<4V-K\G(P5IOD1CJ&M$*65:EC'T :8?S7,=Y*14AV> =
MJ-(]TVD(]POF)PYTW*EMI"<X*LV8!2&RZI"K>,%6">"2+J%SH;8YF-Z94J).
M6R2,JB%K"$J /\TG-Q(/BFP(-ZJ5>XN>'JTVG'M#AJA%NKG?FM&E4HHT3$(-
MVL+>6-=D7$P@HY8(RZ[6(/;X!)4TM!5\LVK(*GB%'0Q\H5E2K#WDH=<-@AHN
M)*K:E396,NETW5D6?%4K+;QK7%X3,;4IM"02I>0VZDK"3FZ[#,GB!>YM>QM\
MAXF:C"2;N0ON$JW7L<O+QG''U0M\-+1-DFY:PX'N%EILVG9:FZJ%<:U%E.>I
M\U(PDL6U3\/'L&R0VB1KZ)_/DGN&X ;=S.AN.ZM!04I"9"$+3E6%**RG.D*&
M1))/B!53W5E-UMV;*W4(6E68DLJ4E69.5(0#D)!SJ &JBFJ+%<<G"S)(N)=>
MHJ1U-4GZA682Y.*[4CPLZ_MC5DL[*T%*0,HH%>EYDD-(MF/I%[*NC/I*M-)R
M';NY%.3AKXLD%!<RN*4WXP4D()XW3_.2,P)L +!12K2J1.9(*K*"+H"5D#*K
M,!PU_FDV(%R=2D%(O6<,Q9+K6)8['EE-AMK,U6W7*L5>QS;J.:0+JCA:K=5Z
M=%2,A#JUV0?J;/+#Z5=K2OJ[ 1T- 21I"RM)AU68:?L,Q]\7$AQ*5H0I:4BQ
M#F5"ED!5P.";:9E%2A9) 4I-YU_=!M60E*UI2HWMDS+2@$BQ]]?7*  ;J!(!
MM7%F:8+(XU8RF"8:):Y1PO+YUPNDQDJO,R5RHD*>E%/'61FYAX%A1+<NEDFA
MKMHA66GH+S<VX*>SD5AY!,E3L4-9_KH)9?$=^Z"$MN'>:I(*BXCZTYKE2KQ?
M<^,*I;D%92"V1O&E/- *!*T)R:*T2$*.\1H24Z^ZT-L>UWBJK<O-I1;[ 5=1
M;15NJ=5N5B@+#!V. 2<9(R8TQ!1I/'4@>H0_NCQ[O):[JLVUZ8E5:UIY"3JK
M-S9$V"9G-U4'*DD.W)0XM"5-E*B&FB^X'!F5NE!H9D#QRJZ00@FJ$R[JR[O0
M*2E:@NZ;N.!I&[.4!8SFRSXH20;9K5]8?BOHDE><1TA[@+U><9*G++79?TL%
M><.Z(^@\EW_%,*UF5*[$3M1(O*6#'+Q,$Y:YU]J[4>-8?'SS(DXU=QB!4#*A
MY8=0O=)2I.5)&\"FFWE%(44KL$NCW*%$ %3H:20:"6"II.[4"XI23<@Y"%K;
M&8IS(U*.:Q>X",YN!O;ZGU(=]ZM7!W P#^<D9U _,!P'^Y>H' YP,'QN<V^_
M,.^OK,KLM*W7F#@CMC PK-TGS"FY:1;%NX)S$,F;D610(H7F3,8AN4P;D,8H
M_!$0TI5:TI32E-*5B>:P9B:Q1Q(J:I$2_8I3=LLC=%0SU,[6PWB97L5GG&;A
M!VDY9RTC/.%)E-^U61=1TF"+Z+59.&[=1)4$ \=>/QUT4.'K#+=N9L2AQ:B9
MPD//'=.95XY<GE82'KDFN[>.Y!=V\=2$+ 1#)Z[=+K.G(,B+K+'=*++J*6'5
MZVMZ^GC5E!P@8#2L]7LS2EE8C5&\T@RA6LE)A!NPE7E->,T)%HJZ56<0U:&D
M1B%9J97*5.BF[E^FG7S^<;BV7J,J>KY:N5UPRX&>MFC-UC.OKMF-:;T]HB<9
M#D1K+1G5X]O#EV>@(M4F=+JS<HF$RO)"M-U!-YTRJF5/5\M?>%X;\(UY*WMX
M?'T6T;7Q$C6VM.US#AG,,26"6M01AVCJ17;-8D]AGIR55B6"36-7<2\F"S51
M)\Y347Y5.4:Z<>/GJNS6'*%+I294X9*(<3%ZJ^1Y-Y%%225>VVIMX&,8R*S=
MRDZ8"+VO5R.J\N0C0@2$#Y]JJ(+*]H*O\U" ?3>K$^9+X?0:IM$<?]D316;G
M;K,+5=8Y^T:LXR7AF4(RDV-D;R3*KL8NP3C%C46CM&KLD)>1*UB$A>+B=?U]
M?)YZ91U>O#T=G"KQFL#8@L'JMZ3H<,8E+8MXRM(,A>1+6-CV2T2YCF79(ETQ
M;/&T2]@821ADI!)T2&E(F.E(L&D@S0<D7MZ^OKI0@'B.%6W \+N#JNTJK2OT
MH&)*,! IPNI^SSA:\#96/=1J+1"PS4JV<1\)(Q,9+041(HO(B&EV24I&L6SX
M5%SJC*.KXS65Z/3X?']/K5(@ <!#56%CX./.\6!P^70CVY$.UOW($3[3(/#E
M,[?N?-D%R\667$A14$ 5(%A:KITJ::4II2FE*:4II2FE*:4KYJI)KI*H+$*H
MBLF=)5,X;E434*)#D,'B4Q1$HAX@(ZE*E(4E220I)"DD<0H&X([01>J5H2XA
M;:TA2%I4A:2+A25 I4D@Z$$$@CJK4F>E$<:2B-?9M['9)"-C6;%-U6Z\GD1Z
M6)[*W9,!LE;9N8Z5KTFWCV,8W1DBO%(N=)&$D7;8CE10J'?16%8RPJ6XN'#:
M>>==+<V6K"&R^5K<>[CFN(=8EL+>==4IC=A^*7]RVLH2DJ\9Q&<C9.4C#&&<
M4Q63%BQXZ7L)PP;32$P]RU'CG%<+CNQIN&2FXT>(TB7OU0\03%3*>:2ZI0;R
M/BN-C9OLMN;*+)(1OI>.91#A^P=O6KYZG#MWK^?:QZ:;6"FT(^*9Q+:NMPY8
M>/%P=PHN\E%_,:;''GHP7AZPE2GNYWG9"&G6VW&FC(4TW%6Z2N3%6Z^X^N8O
M60[D"0EME.;J-D8L7$"UC;:G$(B]V18\%R1&>?8D2$06WY&),1D(9P[$&XT1
MB&UAC6D&*72XIQ^8X&O"OBD\E[7>-3C*XK<H2W$=#8A<0E[QE2RUR0JC&<6>
M)1_#9A"7++E=N;K75$TUS39FH( R4*469C@X.*G(ESR',HMEOKFO?R#J/IKZ
MXZ->ER3L-L\[@S6R[V,(=Q.3/[K;F.1TI4\Q$:+.1$&2"4=SA>;> _7 ,HL"
M</?._E)\...K^ #^AW$?A#_*I[>[^#58>)X(OY#^ZO0O;'S_ (!2NO[IO>G[
MDT^=_*3X<<=7\?\ )W$C_P#W4_&.F^/O/C/9?EST^+C3VQ\[X!2O-B;W#]$\
M]+&@_P#!_*3]_'5_9^QW$_P?LJ!UTWY][\?[O7R:"/;'SO@%)_2;W']$>I]%
M/G?ND_?QU?\ )W$]_P"53VZ;X^\[./[O,?U4]L?/^ 4K])O>8?<G_&I^=_*3
M]_'5_P G<3W_ )5/YM-\?>=G$\>8X>CF!Y:>V/G_  "E?I-[]D^;YZCYW\I/
MW\=7^7]#N(_\5/;IO_ZG#M[1V=?QVI[8^=Q\ I/E[YO?LFGSOY2?OXZO^3N(
M]G_K4_'H7N>3X]+^CJI[8^=\ I/Z3>_9-/G?VD??QU?P_P G<1_XJ?@_L.HW
MY][\>GR=?Q:=M/;'SO@%)_2;W[)I\[^4G[^.K^W]CN([O;^RI_/W:G?GWGQ\
MO1\=/;'S_@%*'_F;WI^Y-9JPWY$RHXS;9@0;\8%=L/NE86MN+W!T:-&M?5]M
M8I6MR"EC5 F1WG:D6)H,B!VJ@M$U!>%,+U$4P(I272<MAP/7>_9P!]=;UHL;
MZ>)N*KP12MBY$8X7CL/%TA6(.K,E49J4V(J;X8C(7>Z"H+&<@(L$&^F%?G?N
MD_?QUCY/T.XG_P 5.NJM^>:/CYGGPZN'GXUOO;'3]/X!2OTF]K_\)I\[^4G[
M^.K_ ).XG_Q4TWQ]Y\9[>SUL?-'MCY_P"D_I-[]DT^=_*3T_OXZO^3N)[OD_
M14TWQ]YVZD\.S2GMCY_P"D_I-[]DT^=_*3O_ (<=7]NWN=Q/=^534;XW]SV_
M$-3IY_0>5/;'3[_R"D_I-[]D^>GSOY20[^..K_D[B0__ +J:G?$<4>DZ?)VZ
MT]L?/^ 4K])O?LFGSOY2?OXZOM\F.XGO_#[JFW\V@>.OB7\YM?T>33K\M/;'
MSO@%)_2;W[)I\[^4G[^.K^'^3N(_\5/'3?Z>XT\NGDX4]L?.^ 4G])O?LFGS
MOW2>_P";CJ_X?<[B?_%3V_+IOCQR?&?F[?C%3[8Z?\ I5O\ M-[]DT^=_*3W
M?-QU?\>.XG?_ /*I_![--\=?%YVX_%P_Q^2/;'3N/@%)_2;W5I_1/[R.RGSO
MY2?OXZO[/V.XGH/Y5/YM1OS[WRZGUZ_44]L?/^ 4G])O?LFM@^)CR+]4SGD6
M+NCSBWKU,6C\9XIHI8AQ2(U^HNCCZ@0%/0F075R)&'*G.I1!95)#LYRMB.RH
M$=.RI@X5!ZW\WF3QZR3U=M<WLKTY3-GL,>@(V.D3@YBN+X@7DSW6PE6)8C(F
M*8RIPUT$QU/;DJS K4@J*4$Y1KY\[^4G[^.K_D[B>[P_RJ?_ #U(>/O#Z3\U
M=)[8Z?\  *5RT[YO?LCG?Y/.#_@_E)'_ )<=7$?DQW$_^*@]W_;^#3?GWGQ_
MN]/ZJ>V/G? *3^DWOV3SI\[^4G[^2K_)^AW$_P#BIU^7_LTWQY(]!/Q::<J>
MV/G<M@I7+^DWOU82/13YW\I/W\E7V_\ 5W$_[?=4_P"S3?GWOQ_)I\_GJ?;'
MSO@%*_2;W[)KT"\G%Y+^N\$^;+9E&(XC8;+[FPXMF*">MQU48P2[!"2ME*L)
MIL[MM=;&HHDW4JZ; S86*)#'DB*"Z(9$J2]"W,X RVL;\;_%85YQTG=+$G;S
M H>$O;,O8*F+BS.(]TN3%R$N*:ASHP8R+@QLJE"67,V\40&B,AO=/M-JU7AE
M-*4TI32E-*4TI6DWE!L69$R_PRVFK8R9K35@9S5:LKNI-WG87%U@Z])$?RE8
M;.!$"@Z=D(F]:)&'^Z73!%NF!EE4BCZ9T1X]A.SFVL&?C+B8\5R+-A-SUHWB
M,.E2V=TS-6-2$(.9I:P/$0\I9LE*B/'>G797&]L.CS$<)P)M4J4B9 Q![#$K
MW:L6AP7]\_ 0JX!6HY)#:#_E5QTMI!<4@'\_<OQ096J-1SUFG*L%/03][F?&
M]&KN)94LI3V,:@YL(9.O,"1J=FQD$?-U;&E.I#Z97:*RHP4PV;**F2.5(?JI
M&RN!2YFS&S^"R8\AEG9[%L1E8ZR6)[KZFXAP;#9)<SNM*S3<:Q'$VXX6&>Z6
M%K"0H%5?'2-H]I(\7:_:7'8DB-(D[2X)AD;9Q:96&L1FG9R<>Q:,ELMLOME&
M'[.X3A#LA2#([BDH:4M2<J:Q+0>+?B)SA,*UW"7"[?LAR<XPL[><5J<N[D8A
M*\7*WPEQF<B#+3E&EZU69:4=PH5Z5<61X]CD:4[<5V'5KY!5>K7,;V2V7V?8
M$C'=K,.PUF,Y#5%[M90R\<.P^#)@1L*W4?$&)4N.PW([JCHBMMO*Q!"9;Z9)
MLV-SLQM)M1M"^J-@^RF(X@[):G=VF$\X^R,6Q+$(V(RL72Y(@O1HDM]V/W(^
MY*<<91ARU0V#$N5J][>!O@VRGC^TI\07$K8/.926QY4*%4,3P-HD[%1,6QT'
M7D(F<LCAVZ%)E8LI7=XI,R5CLK9H"4<6Q3\5&O7[:6>NEOF#I!VXPC%(RMG=
MEHQ3A Q.;B,S%Y,5J/B&*NR)*GF(J$)!<C83 ;##46*M>9SN6,ZZVVIEM"?K
MC8'8O%<+=:QW:5^^*C#86'Q<*CRG)$'#$,1D-2)*EJLB1BDYS?.R9*4Y4&1(
M0VM8>6H^I6O)*]6II2FE*:4JBV.N0EN@I6LV2.0EX&;9JQ\K&.N?L[UFN&RK
M=;S1TU.0X!L/(<IO8(:J2I2%!23923<$<0>NH4D*24J%TD6(ZQ6)7/#1@MXH
MS67QS"^?CH2*KC!RBO*MG+*&@YU6SP[-HY;2"2[?T;8%U99FX24(Z0>&!0BX
M<I +>$J0!8.*L5*4186*E)"%$BVMTBQ[*M;AJ]\@OE";W-PD$D :Z6)OY?(*
MIM9X4.'FFV**M=9QA"Q$[!%;%A7:#R<.C$=E3@$R&C8]Q*K1K)17U6@%7JK9
MFFK(.8Q!V_.Y=&665E<R2M*D*=44K]T+)\;W7$@7/NU "^@) TJ$QF$*"DMI
M!'#CIPX"]A[E-[#6VM<7_"AP_2KZPR,GCQM(.K-)3$R_,]G[8Y18S-@MS2_3
M<S5VBT\=I2I>4NK!E:7DI3D()^M.M4)$SCM*95 "9) 2 Z0$A*19* 2E*"VE
M*R$W6D(4467F&4VM0QF"5$MWS$DW4JUU*"R4C-9)*P%738Y@#QJCCP7\,0BR
M$,31!/1Y!3;E2F+0B02'DB3"Q71$ITA'X.95!E(/ ?%<]M=Q4*L[\\>$B!93
MW;*U^O'7CXJ.K+IXNGBW&EM"KWQO'<D?[T.KBKA>]CXVH)L2#>]DW]R+90L^
M&,9W,U1/:ZNE/J49<Z]:5DY.:<JM/.R4-,K-GRIY+SDY'+R]<KTHXBYXTG&N
M)""AWBS0[B,9*(VDONHSY%Y=X+*L$ZZ*3<:>*0E2@%)L;*4+V)O<4TVK+F3?
M)[FY-QJ#J;W(ND$@W!(!.H%6=7.%C =0G+78ZOCQE R]VJ,G0K$O&3%E:HN:
M=+*H+.JZQ8)S(,(*-24;IC&H0+6,]# *I8@6)5U@/6J7(6E"5NE26UAQ((3H
MX!8+)RW4JW$J)OSO:J$QF$J4I+8!6DH58JU2>*;7L!U6 MRM7VK7##@RHC2A
M@Z*1(<= B2F#(V*V3OH1NS.@M%,4_3T])=LC(!TV0?5B+D>UQU7DD_25>:QC
M\QG)BI4A>?,Y_E+Y[)0G,3HH^*D6*AHLBQ6-%$C2I3'93DRHMN_<>,HA(' 6
M*C<)M=(-PDZIL:K9L!8?/886U#18L)VOR;Z9C7A%Y)-/TH_MDW>S/I!B1\6/
MF5V-TLD]:80TRT?A79Z6?2< $:[7,KJGNA[*I&\.50"2+#@$);L#:Z;H0E"L
MI&9*0%7%3N6KA6072;CCQS%=R+V)"U%2;WRJ)*;$FLP:LU=II2FE*:4II2O,
M.Z7WC>JQSS5;JK6QP[3*7$6TCFCB/L\C+FIR.2I"+H\M:8&.@T1<P-;I2RUA
MIS.NOWDO:VD3%LVR3YY(@D>=.WM_=Y=#V50<W+AY.WG^[C7VB\R<<KXK64<T
MVIMF+=24!>+;XCR$HO-LX&ITZQM7S5[,V6N2<,I='LQ,0:#%_63KP#Z/>MP+
M)N6@E)) %N?78CMTX4NKY>1Y>?6]QR%45CQ,\6HVJBUF2I3%I)V:ON["K#*X
M6R T<O+9%/\ &32VXH;NE;0HE%P-./<7R"F<W:;JFRHK,SMVA_1CD9 <O;Z?
M1?3XOC%,RNKR:'CU<=+:^BK65R)QT,:#3(Z2@;%/6-CBEC8)&>B*+8X*2DK(
MXAL#2)ZM8VJ$U(-G,RB_F<CQTF^8IQ$DL,:]+&HPBC*0!S L>SU/*]_U]NM#
MF[=.=N/#EKZ>PUE(F8^*&X4?BVC5Z/9:R]J6-9]UAN7:8^MM9LKJU(R>1(1.
M+C_/.;,2T/48^!J4[&R5:-(.) )U-^DR:*OV\!%+<->=CZ>/KZ>07-E<>!()
M%C\6GR5<./KOFF.Q&8]E6M::KOB4KM1A[)+,K"C*#C"9>51PT4C0R/ U:XN&
MLG9'CO'82%VB&$B+Q\]<,79X9*#DSCQT X?JN>?HI<A/601YQV:7]/;6KLG;
M^+/U9:QZ#_. K(RJ*CZX2==RI'$>6!WC?()S,U:K5\42-SKSJ-N$=5G4S"Q;
M^_875>R,,RKMM(T4FH\LV\GF(ZQVVYV'DO8<:@E7;\?HX6[.8X6TO6WX!Q(9
M"ON" DX*Q4"MQ] G)C(:+N\O84)>=1D<.*,EWXT%@Y8&L'F'UZ:-Z?,.&<6L
M5M*K;BW33.E'7\W[SZ;WJ=3;B.L<M/-Q/5U=588@KEQ,-GS20NLOD^N8O;X0
M<O+-:)*MLT).O\0D?BUS**K+E58E?EQ.VA"KRS]RM'#''S"S:0PR81ZR\4O.
MGGOUZ$:<]?EZ[U&O$DVM?AP/DZOBOKI7I52I*6F:=4IB?9>C)V6K,#)34;RF
M)Z/EGT6U=2++D-N8G9'BJR'*8>8OF]AZAJFJQJ >RKFTJ::4II2FE*:4II2F
ME*:4KHRCAPTC9%TT1[0Z;,7;ALWZ_F[A%NHHBCTZ_FJA2DZ=?A=-764(<>:0
MXK(A;K:%K]XA2P%*_P"Z"3YJQY;CC,62\RWO76H[SC30_P XXAM2D-_]]0"?
M/6M<9/A2(JN2418$),+%56$M--7+91SVZ?E8U697M"ITSMB*.)!=<SY]N_2,
MPB&Y@=(IP:*,G7.Q?BG$I$QA^(IGN2<['C+;6E.ZB1WQ&3"2,JCD92G=-V:(
M=D*&11DJ4S,\NA8@,!@X7+AXBW+&)X1&FSVW6EN=U8E-B+GN8LM04V%NRG'#
M(D?9*3&@M$.H3A[:)>%W-51%M:ZA)H30S4I;(^U-;68@'3*JA&%82T8Z62.@
MT.<U></4HEDZ,T;$59V8.SMV\>:-:ML*;X\#$&5Q^YF(#T%R#>Q*5/EV.\VE
M04L 3$-*D.("UD.0O'4MW>N+VF$_6L:P26U.,Z9C$7%V<8RW0'&HG<TV+(<0
MIME2CACLA$&.Z66@IC%QNVVXW<K+7XO?+.?_ *2;B-_^CA__ /(/C#6@9]SQ
M_G'SZ#UY^7E7Z4_4Y?R!E_\ K)B'_P"1PNO+W\/_ +O_ 'ZO5[Y34>O9Z_-R
MJ/3Z^O/2G]O]G]O'QT/HOI?GS.GQZ^HGUOZ.5/ET]?ET_P /DJ/\/1?3_#JI
M_;_MTL/)V#L_>?GI;S</BN;>3L'R4U-33^V_\/\ ;PU%_,;7/R=>OKPI3^;Q
M 0_M_;N'4T]?7T4U'D];5'K\^OKK6X_"%TCN+?\ YG.5?9XVC'0]_P"';P_#
MMWZI5_,X>['R'A7$[:?Y78W_ -=\(_\ R>)_X>7X].-5<!Z^0<;_ *_)RKM^
M7K^_]=-.?KZ_XFHYGX_7L';SI_;^'3K_ ,-+#JIYO73J]=*>/_9_8?[;AW::
M?KOQTY\>1J::>OK>_KI3U]>-/Q?VZ:GR>CU^*HY>OZM/-346TUX6\G+7UY4]
M=/D]>=/X._\ ^.A[;=0\M3^KK]?DIJ?7UX5&OKZ^3AU=M@';\'_NU'"WZSZ;
M::_$/)4^OKZ\O3OQY1[_  @:Q_S;^%[;\A-&Z^&H1PU]\K_^\UYST7V\&YEO
MA1M9Z?""?Z\+>:M!]OX?[=/[?[=3\G#A\?DY#]>E>BW]?4>NG73\'30<O/ZZ
M:</70U--32G]O[>W4=7K?T4KWF_X/-_AE92_YLMN_P#RJ8<_%JT_[@?](?(:
M^>?JE/Y$81_ZU0__ )1C7KVU^QK6+7Q+32E-*4TI32E-*4TI5,DH6'F2)I2\
M3&2J:1_.))R3!J^(FIMR^<3(Z25*0_* !S% #;=-]M7F9$B.26'WF"H6)9=6
MV2.-B4*22+\CI5A^+&D@)DQV) 2<R0^TVZ$GA<!Q*@#;2XUKN-FK9FB1NT;H
M-6Z8;)H-DDT$2!["))%*0H?(!0U;6M;BBMQ:EJ/%2U%2CY2HDGTU=0A#:0AM
M"6TC0)0D)2!U )  \PK[ZIJJFE*:4II2L*\0,E=H7&;B:H*4XO-0UUQ1+2;>
MM1RLO.N:-&Y6I;S)C>.B&[=V]E5E\<HVI(T;&M7$J_1,HUB4%9)5JF:_&#:G
M0ES+E4V\D9CE3O"RX&;J) 3]=*-20!Q) O5E\K2W=N^8+:)RBYR!U!<L.=VP
MH6 *NH7M6CD5=>+>5R>_L)V.0"</#^^5>4D$CUN5A,GM:,_RYFF$@DZA6I2L
MD?I0ZK-ICJ7RDSDBL;K%8M3CW$0R1D)A=9OGEN&EH(NWW3NU >.%-;P,L*5G
M6E=LURXEHBZ"[<$V%887*+I/C[@K!/BD.!!<="<J5)%DVW97>R@V+CB;?+B)
MM7%+#Y9RLCBUWE]P@:MSX4Q.(IDDYJU7:,<'O)AG)LV0U"QTG(T<_P C,P:M
MU$;I1LP1]Y?M()*NV3'S4P24Q41"RT7@Q[M.?,L9UDOA)%\Z5M$-&_\ DW&2
MV"K,EPC*D*DAUP-ERV162R3E19HD*ME4EP%8]\AP+L,I1QMG)?$7QG2=:O%?
MJ]!M%5<L<<6-HA=XS ^19N:7RNDZRBQ@*S5HGMJ"96MAC8FER[;( (SE3K#U
M5-"3%X%A:)Q\M1H(4VM;B5@NI);,AM(#%FBI:U6XI47$ENX6L:IMD.:''Y:D
MN!*"FS:K+#2R2Y=P!*;*TN V0L@H3P-\UAGVNY9S_D+&5YF$8M!E,TGB'Q?B
M2-=4Z+6<C<8JE9ZI]>S->V(B]EDBT^P51S-,5XXN[NJI0=K2?R2KA#SC&PIF
M.TZVDFX7&>>(6;9%+C+4PV=$G.E820?Y^9.@'&^EUY;:S:Q0\VV,HOF"7DI=
M6-3XI22+<4V5<WX:ZVG+G'RYKM7<.JT]CY@L16;)./:;B.Y-D52S\?PY3$A0
MG,$I9[ N1W'S5OR?6WEA;+(RK",@'2Q4XI2&GGCO(2SA^=>55TYEI2''4'W/
M=(#@5E3H0AI03S*@-;IK&6[-R Y2%62HY6UV-]P<F6YOJMP%7$!/ 64:HEWX
M@N.Z55MK&OX]MD+$51K,NHL[;#%Z;2UADV.,\_Q[2INGX34FI*1LU=8;$,G&
MVFM23.036FFCUVI#DD58:(J;C8> WF<0HK*027V[)!=C$K2,J;%+:GP4+&N4
M@!5LQA;\PE02A20F]OK2KDAMY(2?&5<%8:(4#IF%[7LG+3S.W'$Z"QFA,?1*
M1H*!M%I<HR6%KVEYNRUZ+R'($PM%*KW9F6UF=JU^A-V.5H/SL)8!N+U"%ANV
MMTD8ZR(\ 9<SI\924Z/-^X*FP7R,AR^Z<NRHA2=V"I5KWN%Z9XV5 T2I>K2Q
MXP"SNAXWC<$#>@6.<V23PS]Q.W&Y1F&8QW693)Z5SG+H_KT)(8JQ_;42L7RS
M2XLXJ2OT:C6,B6V)Q_4%&[&?FY:'CC*W67K\-&Q:1H&Y# .\>*A!>.<-9$MA
M9#SB#<>(2&SG:07%@E"0H_6PHDV6@*&1(4L-#*7,ZEE(+2%:&RP"L97%!"2
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MFF;F:N2DDWCJO(NKC)7'(5B*%-K3D6%J#Z<Z2D62Z'@$D"V8#>('!)"6P+K
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MB',I&+N2AA^Q,I)9G.&(E)24 C"$L+-Q)OXDN M#3[F\0H,&QL%66/K()25
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M#])3YW5SW]\%B'_J:Y_]PTWX]Z:>V9V>^#>,_G$'_CI\[JY[^^"Q#_U-<_\
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M![Y*G!2L'(P+"WY(CFAL?X]JU>(E+,?,UBY4%YCEP?*S!NV8LB&N%P98=Q7
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M'@2V(J7$NKFE"56]9$52+HI+IB!DUDDU2&#FV$BA .40YBE-L(" _"*4WM*
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M4J_Q-_SBEO\ 1Y_W1^(<W)^]W+OS;#NI4"A=>NTG5NXVPC!2P]?A\FX>L0=
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M=/"3J_Q^^"EN_<O)T]8O .;G#?X0B782;#NIZ^NM/,73[)U?O#;\XI7Z7D4
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M\[&8Z3OX1%6BUZ8-1D>U',K5R1S;(KB_(R[9>17Q\2K^9GE5M+^ORW^+]XJ
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M=<_$0\ZRW(CK??W61*4K/YP8%#VNV9VEV>V9QS"Y6!P-BHNT&-8T2@K5M"U
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M%*J3YE'AO1YTQ%T '**J:B6Y-P%1,Y-^8I@!2MF?7:F=_K=6.X1_7^*[@\V
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MI2GKM3/MNK'QO\?Q7Q#F3/\ MOXJA#IF_>G*8@[&*( I0+M3!$ "W5@1$2@
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M4S G\C+3^'QO7>(B/B'4=/8=V6_"<9Z_XS&TZO\ 0O)U\>)J.]['6O7^L/\
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M#IL:!_DXY^E4_L_K]>=2<1'WG_WA_P .NFGK:GSO9/;?X5<0&V^WZ#;SY/\
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MP.0I4BB0A@2+YT%3&.8V=W8BUC"AGR(<!MI_Z7GKJ;D7\7+85RG<ZN4A\?\
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MD6(HF<VY!(54WKK1UKJ<M,OX"-S,1]-Q4E'Q3Z(0D: =\E)2<#'VB.CP;A7
M666?5V5CIIN1OYPZL<[1<IF\V;<%//V>>KT]!2FVWKG91Z;;]EI^^_3X72J
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M!_3C'T7KU]3WRSAD^Z3ESQ'Z@JWXEY=OJ=\!'F#QY@ZB)-RC'MH.BG\+QO\
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M8.^J_% P)E_T"%$W,<3G,I3T'*=/HRLG02CMV6H=0*"8"4?H5WV.)#&-L("
MJJ<@E $@34J/04IMMZYV7?E$.;LM.WWZ_#^I/EY@WV .7EZ!N41WW4J?0<GO
MOZXV3;F$W+V6H[;?!^!]2O-RAL.P\W/\,VYQV+RJ5Q]!2FVWKI9M^4I>;LM.
MWW H )_J3Y>8P@)S!R\G,80*0I=B@I7+T')[B/KE9 ZF';LM0V#FY]@#>J[[
M$YR\NXB(^;)SB?=3SBE/0<I]N5D^+^U:AUY>7?\ <I\?8>;;;;F-R<OP>52H
M&"E!#;USLH=#!N#6G[_"YMAZU,0W)S!R]-AY"\X&W/SJ5R]!R>^_KC8]N8IN
M7LM1VV 0$2?4KS<I@ 2F'FY]A'E.4VQ@4KCZ"E-MO72R[\O+S=EIV^_P/A_4
MGMS?!-TVY/S0_P #HGR*5/H.3WW]<K)MS<W+V6H;;=?@?4KS<O4!WWY^@?#V
MW 5*@(*4V^K.RCT*&XM:?N(E$@B;I5 #<_*8#;   "A^0"""8D4J?04I]N=D
M^/\ M6G_ !B&*'[E/^+,8%">TY"@?G3$Y#J4]!RGVY63O+^U:ATV,)A#ZE>X
MX"!#;]0* "42GW.*E1Z"E-A#USLN^Q@W[+3]P$P; 8/H3VW(/4NX"41#X8&#
M<-*5(P<GN(^N5D .;?E!K4-@#X?P0WJHCRCSE[Q$WYD38P;J><4IZ#E/MRL@
M_!V_4M0[^9,W-TJ@?"V(8G[WE54'EYP2.FI3T'*?;E9._?\ 4M0Z_ $NWU*]
MVX^<Z;#S@ ;\FY!4H$%*!^[*R#]+WM:?UY3E,(]*H'TX *9MNXAC"3E/RG*I
M4>@I3;ZL[+\;KV6G[]2E*'[E-O@B G+T^F,8#<Q.4A5*GT%*=?HRLG7E_:M/
MZ<HJ"(A]"GQP.4#;[[ BGR<@BL*JE/04I]N=D#Z?]JT_XPE$!ZU0?TO80)X"
M!C>< X\HE4IZ#E/MRL@=0']2U#N AR[?4IW")RJ#X\Z9  0(*A%%*>@I3[<K
M)W#^U:?^_P"??ZE.\"_F8>')U$!4_--*4"#D_MRL@]0'JUJ'=R$+R]*J'03%
M,H/QN=0X ()@F1-2H]!2GVYV7N /U+3^\#&$3?4IWF 0*/Q>4I>4I3<QC*5/
MH.3Z?1E9.@F']2U#J @F %'Z%>XO(82[;#NLIS"8 1!)2H]!2FWU9V7N*&_9
M:=OT*("/U)[;F$0,;IMS%#E I=RBI4^@Y3[<K)WG']2U#XQA, ?4IW)@($)X
MB4H"<3GYC&4J/04I]N=E#NZ=EI_@0"C^Y3XPAYP?],1 O*GL0%*D8.4$/JRL
M@=!#<&M0WW$RA@-UJ@AN4#E('3EY44Q,!CBL=52I]!R>X#ZXV/;F VW9:CL(
M!R_ 'Z%M^4>4=Q 0/\,VQ@V)RJ5Q]!2FP!ZZ67?E O-V6G;B(=YQ^A/EYA\0
M  )["AI2I]!R>^_KE9/IC#MV6H;;".X%^I7?E*'P2]>;;Z8QC?"TI4!!2FVW
MKG91Z$#<6M/W$2E* FZ5, W4$HF/L'*!CFY (4"%(I4C!2G7Z,K(&X'[FM/Z
M<P&V$-ZH/5/F 2;[@(D+S@<!.!U*[+2*?MG)%UK+-OTB\W,S=H5PC93<AB@!
MS,:^R=ARF$%"^;=)_#*4#<R?,F92JWI2FE*:4K2JS\'+2W3(DF[YVJAQ^1+'
MDZN4Y2H,U732PWK(T%DB\LK#/KS*K>RUZ4D8^:CX>+"OQ"T0QLKLLD^L0,(]
M-&0;>O81^OXJIR]NE[VMV@V]/RUCPWD]8$EA82+3(16\.RR&.2B,#4**7G$)
M7TA7SI5N+LAIDA8NA-(:L1;-I54H95-&95E9XSU0C\D2TG-I\5]>%K#2]M*!
M-C?MO:P^6J;%>3K81-:L58;9/: QM5>=5:0\_C5A,C7X5*,<Q\,CCQQ:[38Y
M6GN!4>N5[0\5E)QQ+MPCXFLGH\3"PC2.B_ZN?5;U'549=./7R^/R]?757>>3
M]B74K%RQ,CBS>0<K ^B7L?30C9-"O5^Q6&RH+/GD;:F2,]D5\]LCIM,W2PLI
M6NS3%E$^E\=OI&-;2)))N;D?'ZZ=G'J(ID'J.7S]O#LJB5SR<$!5F,&RC<DJ
M.C1#BMLEW5@J;VSN'M;JDWC2<BE6XV"\2)83(2Z^+X=K*W2&!G"+,Y*41C*)
M#B2)-&,W9_CYK>CL\M1DTX_%IRY=>G7PY5E7*7!;#9-MUQR&KD:UPMWMSB1C
MC/T1=OH"/H;S'J=*1HA*BK-(0KADWEV[:]*3!DT99Q82+$*LW9+ BE -K=FM
M5%-[F]K_ #>O9UBL>/O)^(2CRQ2LED]B[E[E&7:+M#I3&C%5L=/(ULR_9+/)
M5YDZM3GT'/QS?+3B/HLRZ<33BK*PH.WA;$UF)&+TOI;EI\7ZJC)VCA;AY>WX
M^.E5>.\GU1V#Y64-:U'DH,C/R3>5=52*6E6R\PSQ*U9&3D5'AW?GH0^*TW+!
MP54BI5["^.043( 9ROZ^>Y/RCR&VM"@>OF[?6Y-=>"\GW5ZBC5G%0N;>%GZ<
MCCLT3*^HD8=L[D,<UO#$.P5G&#"8BG4C&S$IAMG8)F-0EF"RSN??%0D4'+5&
M04DF_+K^6]^7"_RTR=O"UM.>FOGM_C5$0\G!5$*C$P)<B2 SD2$"J:RI5PT4
MO-.*Y#</4;'M9[U=LL)..:^HZX?H]\[B(ZRQ+D269\@PEHY>/:OEE_3PO?R\
M?B]';3)I:_Q>3M[/CM68)SA2D5:]CFKU#)#>KQE/P9<>'Z=4?4M>S2$U2[P-
M&&8?5YT[N3%.LV)L2DI)13R;;7A@W3D5.V1D@HV(HK%_3>_KUU.70"_ $>GS
M\JQ%+^3EK3YPY&-R/)0S(P]J;H-8>71=.GK/)[?)D*QL+R-O$6G)5MDY8L8E
MZ2(9UN]R+--8B.1(Y@9I%L%_7S6X?'Y0.JHR=OD[-?+?AI\=4Y7R;\:=^B[#
M*BBS2/KS&&B8EY6+'V)JNV:8[(95PO$Y0AI19HUDL=M)2"=,I",O,4,DJQ=W
MV89Q4&G'3?L\FO =0^<WJ,G;\7[ZS9P^<'L/@*[OKHUO,Q<'+FIGK*)YIL];
MR6\@A2"3+EX="P*U?L9EZ)&&@HZ"I]=/#LW#A@]?SB2$<=E%_GX54E-C>]S8
M#T>OJ+ 6SD'@A0O3*CQ9<G2$1'4_(=\R$HF2NJ*NG[V[9[1SN+)NY8V:'(@@
MS?HA5W2<RVLD=(18EDVT5$S:*#Q(#;U[+7]>VUJ%-[:]?GN;UA*4\GK.RUQ:
MP#>:JM<Q37*]75(*P1S)Z2]R5LK3#A^0CV<HE!+U=VSH+MYA(%I6JQ5I9/B^
MEG[N.M*;R4:^J\YC\ODL;W[1KZ=.K6G)YAR^(?J.G#6^IX96K_ -"5FTT6R1
M-[(U]3+)1;(/FJJ^],.U:A#XWBGL4WF5KJND,+/EQC"D[#:8JXFAFCV04CE@
ML+:!LD+%]+?-\QJ<G#7J^+_#S:]EO0?45771DVRKV-D&:"PMEW;%VV1<%^F0
M57;J))K!MUW2.<#AMXEU=86EMYEQ:<Z6W6UJ1[]*%A13R]T 1QYUCRVEOQ9+
M#3A:<>CO--NCBTMQM2$.#M0HA0\E8%KK9P1G7'"E02E/1E295V1K;D@ M7Y:
M-CV31RDHV<-W1" '8%46BXH(IOXIRV>Q1W*3I0KKJ)BT%V8D8@IG?SW9;,Q!
MTEL/.NN((6A:"3]=2IQ.=1:?2MM\(4@;OS["65]RX4X<&1*$/!X^&2L*=2 O
M#ID:.PRXA33K;B0E/<ZVV7"VE,B&XU(AEU#Q#U5J\2_+8Z@V[.)35QI:'TR\
M1\X=NR+*M8IC'5A5=03&!TN/)* R-R.4&,(P<R*2:SUL9:Q-?:,/$%YP1,<A
M-1VE6"W#'<?==G)2!;=H\9C>CQ%N2G4,DI:6$Y6%Q)'?;!&@VH'"X^+2)SZ"
MI;3 F,PH\;"%.JN2XZ2F9N;AUIC#HKLI"%R&2Y^?+C2Q+E2^\:?%!*T;&M^N
M46VN6-&+F2JM.L-@8-WI.'+":YV:SR(CGB";HB"Z"QVZBA52I+)*"3D4*(_F
M_P#5-;([5XYTB1)N";,[0XQ#3LOAL=4K"\&Q'$(P?;GXLM;*GHL9UH.H0XVI
M:"O.E+B2466"?U:^I1VUV.V?Z,IL'']K-FL$G*VLQ20B'B^.X9ALI3#F'X.E
MM],>9*9=+*UM.(0\$9%*;6D$E"JUR^9MXB.[W!LR]=O\F-V\-^NWH3?KOO\
MS>'3YW'1STA<]@MLO]V,;UZO]! TM:W WOI7TS[*71GQ/2)L-I?_ %LP&^MC
M^,/-VVJ X;>(?O' ^9?D_0QNO7K_ /4>VP:GV.>D.]O /;&W_JQC>EK@?Z$#
M>UNNW'LH>E+HSN![(>PW:?"S >!\F(<;_/4_,W<1 ;_H#YE$/$!QA=?P!_B0
M1 0W_P#B/34'HXZ0O@)MEKU;,8WSX_Z%J#:_9V\*CV4>C.W_ .L/8<'K&U>
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MZB9J\5<)(68A%6SULY<(.H\P#'N$!<)+M#$5 JLYU7!N>KU];U&1(X"K8O\
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M57K=CF@WVQ05NNF"4+/9JQV<8*:F6=$>R,>#*0+*LDDEUK,(J),Y1NC*,D'
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M/:CYQ CI,ZC4Q_HHY=G'FEB)[&'X2*@GY"<ASJ5V_3TOU^@JQ_%_;M0Z\PJ
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M#-@XG(M!XNDF<C55XU(X%(SQF#A2N]Z>E]M_4FR;[%';MM/WZ@(B'U4[;E$
M*;KMN8.43%W,"E3Z>E_M*L?Q_P!NT_XIC  _53_Q@ !B>(%,7G AN8I5*>GI
M?[2K'X=>VT_Q*!A_=3O\$1$@_P"D B7F)L<5*I$+?4[&S7?P%>E9EDUE9Z"<
MN8Z5I;I!";J\Y*5JPQ*BJ=K$A7\/.P[^+D6XB!VCYNJT7\VX0<)HJ5W2VMV9
M^I&%J4^+U%LW>*H=LJ7,FS=++H(.C!ZS_I2BS5TF&VZG,V4^!L*8G4KL^GY?
M;?U)LF_*!N7MM.W 1VW)]57+S%\1 PDZ#RF-TW4KEZ=EM]O4NQ?3"&_;*AML
M!M@-]5&_*8/A!TYN4/A% VQ14KCZ>E]@^@FR!\$@[=MI^X"8"")1VM6W,F)A
M*?81*(IGY#'**9CJ5(STN&_T%6,=@./1[3^O+S; &]I#JIR@!-]@#G+SB0 .
M)%*[3.6D7+E-!>KS4>D?FYGCIS7%&Z6Q#& 3D8S[QV/,8 3+YMLH('.43 4@
M&.52J[I2FE*:4KS/M6=N*2/<I$:U^/9UY7*O$;7&-C9HC+3TC T?)4E TA"0
MJ2]%;L81HV@4"E932-EEE;&BW0D'*0J/%!1D#77J\G$$C6K:E'R"Y'7>WH^6
MLG8ZLO$UD><-$HVB(IJ.&[% 43)SVSX\*]1RQ-1-AG'%SDJR1![!C HSN/TL
M>V"N3$6H^@F3N]3$>K'.G,"0C<;>GU/+KOS_ 'U J/5I:_;QO\5O3RX5U\@V
M[,-EN3MI4,CVN@QL%Q-5+#CZ(JM7Q]-"M3)?&M5N$E89=Q<Z-;G;5\I)S*XL
M'S-=C&MXE=JFX:N'7]T Y<!PN#SXV\GK>FI.AYVMIH+<>'/]U?/.?%+D+%UJ
MNL%7Z/'3Y*XO3(^-C5(ZQ+3KV,LSBF$F,JKR!E(2E)4*HC992*DV,K9:V*TM
M7G1U+9&H'61:/7EU_-ZZU!40;:<NN_EJU,2<3&9K &:[C>ZH[BX2GXH:Y"KM
M.)!.G";>4#']1LSN&9RT1#KS-@2/)R$LBB#5&0?F34!%)NHNW*F62.&NO ]F
MOKP'DO0*.IM_-OV<!^_G5EQ''!G23KTO9FN$V4DPK8R$>[9(L;"WEK,^.YS@
ME#3,"2)?VV+;08-,85F0>MVDK:U7S2X%/%21C%C"R,6'I^+A\_9PJ,Q-]/)H
M=;WU[ +=NO55PS>>LR.L Q=X0O,1&2KW/N4JPYMT'7#PD3)8]K<YD1K5$ZZ^
MM%"R'"5WTJC#5L(F5NL(O&V,OYQ)7%C*V"*L)A%CYA\@J23EOS[.'/K'"K!B
M^-KB#B98D1)8K<6HKYPTD62\I5%:!*I1;ZI4*0&NNX8]KDW2%H@/3LI;IYO$
MM+;YQ@X;0B18UHU>69E58&UN)XB][<>?H%OEO49SY>.MOFZN//S5GRB\0F?[
M"CD1E+XRK9Y^$QSDJQ4IK!-;4BC,W"E0>.I:'@G@S!B@NVLSO)2$*S*U5:N1
M7J,P]*<P2?8(&FPZ_+V?/_AUZ575KY[>7]]_E\M8VF.*O(-"C*T-/=V#B)&R
M/8LLU.3U&C:+%5&>- #(.\>M95BC2F#F8GG8@E'11HZPVNDJ,WK.99W"2D(Z
M,:+<^'9V>O#Y=1>G,1PUY:CGU#05>W#SG',=JMM?BLAF570L5BG8$(MQ7&L&
M[8L8[!&',AELA#H,6JRK%C;IFU5U^8_G&XR%IC&8JI*13=N81QM\>AY\!\OZ
MN%2DDD=ODY :W_5VUZ ZBJZ:4II2FE*:4II2FE*Z,FLY;1L@X9)=H>(,7:S1
M#_/.4FZAT$O_ /(J4A/_ -[5UA*%O,H=5D;4ZVEQ?O4*6 M7_=22?-6/+6ZU
M%DN1T;U]N.\MELZ!QU#:E-H)Y9UA*?/6N]<".)$55FXLCF%A7]49V%2>1[,D
MK/3\PQ:/Y%Z]=OV[MH=[*KO9)ZOYQOVIR<O9&RJ*3-9!;K9A>[HG.(AHDR6I
M[L,1E9U)BQ8[JVF6FT-+;<#;"6FFT95!M .\<"E.)6GS;">YD8?@S+N*.P84
MG!V,27B2-TA>(XC.89DR9#[TEM]DOS%R),AP+;+SJOK3*T(96VNMUAPZ&VTR
M1$3C)SD3:(N; 4U6YY& A4XM]%RSU!8QUS*Q4H]39,^TG.JP)9GK 3F$.F--
M2CN#$F;)W$:1!?C',E89ER2^T_';4@! 2^PTIQS( EXPFG;"XK/PUQWOW@,D
M9NZL0@XM$Q 64TJ3AT!,1^)-D-+)<*X<Q]$=@.%2XR<8?8*C8U^?GC7_ ,-'
MB;[^EQQO_P#FZ83^4!_#UUH&/<G_ *7ZAZ^FNX?]T/\ H_K-:U!MN'7IOT#V
M?P]/]O\ #J]5FHVW_MX>WO\ X>[V^T=*4$/Y]_YN_;J.X>SQ'_:I3PW_ +?A
M_GTI4[=/'<!#I_;;;_Y!\NE*C\?A_P#';^WR[;] TI3?V_+_ #C_ #?S^'3;
M2E2'?[!_]WA^$>GB'7\6E*=W7^W7O_%[-OYO%2M@.'G]>,I]!_P?LUB(_P#L
M-(]_X1V]O?OMU#:E7\W_ *2:J3S_ .B?D]>O]=:_[==A_M^+<!_!XCT]NJJI
MI_./4=MN@=.OCT$._P#$'CT!2HW_ )_'V]?P=W3^'^#2E/Q#MO\ V#?;^WLT
MI3Y?;W?VVZ_BV_!I2G_OZ[^/R]V_@/4.OA^%2G=\H^W??;\ []?QZ4J?$=@$
M0_!_;;IW?@#II2H_%O\ @VWV]NWX]QW_  ;Z4IM_;^WX]*5GW/H?W5B'_P!0
M6+/';_%+C\/_ ,/P!JE&F;_I*^,WJI7\W_HBL!"/>'_N^3Y!'^?554T_MU_M
MX?+_  :4J?X!_@#H'X.G7N\?]@Z4I_/[-_ /Q^SKUW$/P"&E*SGPQ=.(G"7C
M^B=3=]O_ *\9]/\ M_\ B&J5^X5_T3\E5(]VG_I#Y:_5'K!K.II2FE*:4K7?
MB0PE3<[420HL_+0U8DYDL1YNQ.8B(DI92O5NV5VZS5?#MB["1-7I96O,4YQ.
M,E8Y5N0&\BF[;NVC98JE>?-#X$^'>)L#6F-^(P9VV8[J6/H"<=BPJS:]3M24
M914?98[)-O,HLXN,1DO']ZD*'"IO#E4J%7N,&2LN%)."B'P*BWK^KR<Z[U*\
MG1@J=@+2_9Y[D+*%RL+QG&6Z#;UZ'GJM<&=EQFK:)"FR!'3KU;ODTPP^6$L3
MN":QA%AG+"Y9PS.'4;0J*HMPU/:.1\OKPTJM6C@KP'"$8VZU9FJL,[CV,1&5
M4:O7:9186O3JF6JEDJ->8^B:\=\XK,Q-NL?OJBDXA2OI=ZVFK*J19^\6<-%5
M555:EP.-)' 9<-Y'O^.:Q-N<IVNRF8XPAX)U58AQ8L8^Y6,? Q4M$5A)M?(N
M(D N\!9V]>CI"M9#<1TZG&2B""J$JJ+:<M>H=?IKG8_)QU&5*UF\97\\8_=L
MW-<>S$.>/@19H6C(.-IG*5XBI*!C)8[V_P Y4<?2%#<=H*R"496%VC*3C/L2
M(Z5-92S-Y/\ HV8<G+Y(4OURJ23FJ(U!Q3H$K *PK&A7G,:]'LJI2J$/)6*L
M8#MSGS1B&*^X?J='('2C9FQHO5*L(/)@XN1BK,QC+2I 2-EN3RQ+S]=I==AI
M4D"O?JAD!O3%W#0Y57L0E+4]JLZYU4F[V3?OIGL#=V<I04K+KO@:QTZHM%QL
M23.VI-'S(TRXA5T*]"EKDFBFZ:O)*CNX("!%EK,XND]/+(%;&([/+2)UVZHN
M%>=2L!K>2SJS=X$A7\NR\)(LJO=ZI#2P46N.YMM%9 K4;3I9A*RX/&KR<AJW
M6V!V.-X-P=O'TDRR14R2D:U)%J*578CR86-6%O:V>4MPV=HAD62OBL%8:+6Y
M5NZ+,7['619B.6D9!5Y)F7F9C&D%&2:QG!X'U> \=&5:+6%=ZY4J[VO BSE\
M 5[$-IMYV<I'WRP71X]1;-;Q&HQKZCVG$=)IY%+!&0)IQ3$N(Y>JUZBW9W$1
M$N6XX[J^1'\0>0&2B7BE?:Z>3[I]HQ%B7$$;?9RM16++/,7$)F/A(P)FQVB5
ME!FD[6^>LUXUZUM[&1W.2=3>N"/D'DF64CWKM>/>Q2E8LF/)8U2:&J)*Y>G(
MUM482;@F U^CU> D724SCZ2QJ^EI>0BU6_I^Q6:"D1D<B2EC;3*=RL+9%X@S
MK\8H[AG*E=FG>2MQC7+2ZLLK=7D\VD[0K:Y:I)52/AZ0H+O,<?E][1XRG(RK
MNM1N*SOV!FK6CJ13\6\I(25E6FG;MV9H52JM5O)D46G(1#>$R"_.UAVF.&S:
M*EZ159JN ZHV,Y3'#^QDKC\JD26X3J\W*9 :V)5!=:&R"X]/*MYE-1^S?J5Z
M=:4II2FE*:4II2FE*:4II2FE*:4KHMXN-:/9"2:L&;:0EA:C*/4&R*3J1,Q1
M[,S,^7(0JKHS5O\ W.W,L8XI(@"1!*0 *"E=[2E-*4TI32E-*4TI32E= \7&
MJ2;::4CV:DNS8O(UI*';(FD&L=(+LG+]BW=B05T6CUQ&QZ[MNF<J3A5BS45*
M<S9$2*5W]*4TI32E-*4TI32E-*4TI6,I"B2:*XC5IJ&BXTPJ&+!3E4;SD5'G
M<'44>J0QH^2KDBR[:JLJNY;N7\@T[0H95NW;;F(;<M8FPI([NC2'GA8&5%GK
MBONA"0EH2-\Q,9<W24A*%(:9<R#*I:N-<K)V?F-K/>>?!AQ3F*</Q#!F\0AQ
MBXI2WU03%EX5*8,A:W''4/293(=5F::;&9*KBKE8"&$[V0?%FIQ5$6II0T;'
MQI6D?SD5+#Q;5BB3L<0DN45R-UG#UTHN857;UT<$S$Q)DWNBS;+7<T9*@L,!
MYU[.]8I,A];JCO)"DG(5I0VVE("6VFP5 [+#,)[A*GY,@3\06E31F*BQHNYC
M%27!!B-1VP6(2'!O$M..R'5.$K>D.J"2G#M9X?*PED7/%XO%6H=M'*61:Y;*
MZK)U]A,RD3"PN&,58X6C'Z\M&'\RJ><HLQ)H(,EW#7L4@U5,H1VHY01P@2.!
M(YZ&MN4@\0#Y0#60?<6P[]RC&_\ (BL_T9IF5[X^DU&1'O4_V1\U/<5P[]RC
M&_\ (>L_T9\HZG,KWRO2?7D*9$^]3Z!\U/<6P[]RG&_\B*U_1FHS*]\?2:94
M^]3Z!3W%L._<HQO_ "(K/]&:9CUGTFF5/O4^@4]Q;#OW*,;_ ,AZS_1FIS*]
M\KTGUY#T4R)]ZGT#YJ>XMAW[E.-_Y$5K^C-1F5UGTFF1'O4_V1\U/<6P[]RC
M&_\ (BL_T9IF5UGTFF1/O4^@?-3W%L._<HQO_(BL_P!&:G,KWRO2:9$^]3Z!
M\U/<6P[]RG&_\B*U_1FHS*ZSZ33(CWJ?[(^:NZRQ/BV-,X/'8WH; [MDZCG9
MV=1@&IG,>^2,@]8N#(QY!69O$#&1=-E!,BX2,*:I#D$0TS*ZSZ33*GWJ?0*Z
M7N+8=^Y3C?\ D16OZ,TS*ZSZ33(GWJ?0/FI[BV'?N4XW_D16OZ,TN>L^DTR(
M]ZG^R/FI[BV'?N48W_D16?Z,TS*]\=.&IID3[U/H'S4]Q;#OW*,;_P B*S_1
MFF976?2:94^]3U<!3W%L._<IQO\ R(K7]&:9CUGTFF1/O4^@?-3W%L._<HQO
M_(>L_P!&:9E>^/I-,J>.5-_(*>XMAW[E.-_Y$5K^C-+GK/I-,J?>I] I[BV'
M?N4XW_D16OZ,TS*]\?2:9$^]3Z!\U/<6P[]RC&_\B*S_ $9IF5UGTFF1/O4^
M@?-3W%L._<IQO_(BM?T9IF5UGTFF1'O4_P!D?-7<>8FQ;("V%_C:A/19LV\>
MT%W4(!R+5@T*)&K%N*T>?S#1L01*@V3Y442B)4R% =M+D<">OC4Y4^]'5P'D
M^2NG[BV'?N48W_D16?Z,TS*ZSZ3494^]3Z!3W%L._<IQO_(BM?T9IF5UGTFF
M1/O4^@?-3W%L._<HQO\ R(K/]&:9E=9])ID3[U/H'S4]Q;#OW*,;_P B*S_1
MFF97OCZ33*GWJ?0*[;#$N+(IZTDHS&M"CI%@X2=L7[&H5]H]9ND# =%RU=-X
M]-=NND< .FJD<BA# !BF 0WTS'A<V/'4U.5/'*+\> K(.HJ::4II2FE*U3SK
MPG5'/%F;V>=LDQ#.DZPWJZJ#6"I,\F#:.=6%_&N(Q6X5FP+P"JSNROD+2G"J
M,T;M!I,ZW9"O85)1HLI6JUF\DYB.SL;:U6REE.-5NTS9IV<7AC5.)(B]M\)-
M1$NW@F\;7F@5^):'G7+RO1$8HBPB4FD;!KHR5:2>PT@I5X1_DSL7,'I'Q;]<
MS*@Z4*J"4)CQH4\8MD57**IDC-:@DJSN9[*NLV#);11*\)P)@CTI8CLA9,%*
MM9YY*'#3AZ5RAD#(#%NWQU 8VCXMLWJ)8F/C(2KXCJ0R[>+"OEC"6)S'8C9.
M4YM-FG)MY&S6!91V[;)P32'4K)C/R=F)D;8YMSVRVB4D ;E:Q";N-I@)Q (9
M.9Y593(*)UHJ\G<T)Q%W%N;M*J.K#*5]RWCY)VY4CFSG2E;"\-?#] \,^,&>
M+*U9+)9X9A)O9%F]M"[5P_:D>)-$?1[=1LW0$K%'L@+(HK&7!LHX7;L>QQ*4
M?%L%*S[I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*L2Y8UI]^48*VEC(O#QA'*;(6-DLT""9'8HF7
M!0M?F(LKD3"@ER&=%6,EL8$13!10#9,>6_&"@RI"0L@JS,LNZB]K;UM=N)X6
MOSX"K#T9E_*74J5EO:SCB+7M?W"TWX#C?LJROF<\2?82P?E$R1_6[61WUG??
M&OS2)]!5GO?$^]K_ "\CZ6L43]'PZUG'E3IF/KWD2U1OFO3+&!R/>64-6S+D
M*J@E9;/+W=I$1SQ9$X+IQ#921GA;F(Y&)!LHFL??18^(+BMXAB6(P<(@OYNY
MG941EV3,"#E4J'!CQ'9#S25#(9#B68F<%L2"M)2.+Q/:* SB+^"8#@N*;4XU
M$R=WQL-DICP,)+J0MI.+XQ/EQX$1]QM0<3 97+Q,M*0_W &%H<-"]2JI$I'D
M;9@VZ(5Y!15-_.4;--SR&$/Y@PE<*2D,QLT58#IM1 W:RPD7-N&W*83M^0IC
MERNYD2%!F!M%#5,4D*9BXIA#>$=TY@"A+$EUN1#"EW^MF5(BH7I9=R!6N\(\
M2@H5*QO8?$&\,;*TR<0V<QUO:GN -J*7%S,/C]PXJM+1!WPPV%B3S1"BMK(D
MK&887!N#K'%,)R":RLM#RC9)Y'2+')>1G#1VV6+S)JHJDMXE,40Z"'0Q# 8A
MRE.4Q0YZ3,Q:'(>BRDB/)8<4T\R["BH<;<2;%*DEBX(]!%B+@@UW4 8/BD*-
MB.'/-S8,QE$B++C2WG6'V7!=+C;B'BE23Y;@@I4 H$"I_,YXC^PE@_*)DC^M
MNK'?:=]\:_-8GT%9?>^)][7^7D?2T^9SQ)]A+!^43)'];=.^L[[XU^:Q/H*=
M[XGWM?Y>1]+3YG/$GV$L'Y1,D?UMT[ZSOOC7YK$^@IWOB?>U_EY'TM/F<\2?
M82P?E%R3_6[3OK.^^-?FD3Z"G>^)][7^7D?2T^9SQ)]A+!^43)'];=.^L[[X
MU^:1/H*=[XGWM?Y>1]+3YG/$GV$L'Y1,D?UNT[ZSOOC7YI$^@IWOB?>U_EY'
MTM/F<\2?82P?E$R1_6[3OK.^^-?FD3Z"G>^)][7^7D?2T^9SQ)]A+!^43)']
M;=.^L[[XU^:1/H*=[XGWM?Y>1]+3YG/$GV$L'Y1,D?UNT[ZSOOC7YI$^@IWO
MB?>U_EY'TM8MLU$PS%3BM1J]#O>0+FW10<OX*N9$O:+6!;.@YFKBT6&6O#&$
M@@=)@*K1DL[6F7B("NRBG* &5+O83&)/Q1B$[$(&$X:M2D-2ID5E2Y:T&SB(
M,./$=E2RV=''4-IC-*\1V0A9"3QV+[0X;"Q%>!X/A&)[3X^TAMV5AN$OA#6&
M-/)S,O8SB<V9&P_#0\GQV([C[F(26_KL6"^T%+%#7Q_!0!.W7/ %Z9028"=Y
M*TS,]TO;B+0#?=T_@&UDAYYPBD7X2X0$?.N$R@8Y4%"%$VLE+4>4=UANT\%R
M4=&V,2PAO"D/KY(:EK1)B(4HZ),QZ(@FP*P3:M<YCN-X:#(Q_H_Q-C#DW4_-
MP#'&]I'(;0XO2L,:3A^)NH0GQG$X7$Q-Y(!*6EI!5668/!^#++$1\] -967A
MI1L1W'R+')61EVKINIORG34+;N\! Q%"& JB2A3I*D(H0Q0T$J7BT*0]$EI$
M>2PLMO,NPXB5MK')0+',$$$7"DD*22D@UVN''!L7@Q<2PQ]N= FM)?BRXTMY
MQEYI?!2%I=Z[I4DV4A04A82I) JOS.>)/L)8/RB9(_K;JQWUG??&OS6)]!6;
MWOB?>U_EY'TM/F<\2?82P?E$R1_6W3OK.^^-?FL3Z"G>^)][7^7D?2T^9SQ)
M]A+!^43)'];=.^L[[XU^:Q/H*=[XGWM?Y>1]+3YG/$GV$L'Y1,D?UNT[ZSOO
MC7YI$^@IWOB?>U_EY'TM/F<\2?82P?E$R1_6[3OK.^^-?FD3Z"G>^)][7^7D
M?2T^9SQ)]A+!^43)'];M.^L[[XU^:1/H*=[XGWM?Y>1]+3YG/$GV$L'Y1,D?
MUNT[ZSOOC7YI$^@IWOB?>U_EY'TM/F<\2?82P?E$R1_6W3OK.^^-?FD3Z"G>
M^)][7^7D?2T^9SQ)]A+!^43)'];M.^L[[XU^:1/H*=[XGWM?Y>1]+5JV_$^
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M*0<'/) HTNG8B0E1;7B4-#J9#K)2IN0$!#6*HP<O%\MAD!4IUHA!4%[I2ED
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MX<*)-&R0+.G*JKETMSN'*JJZJBAM;*DOS9,B7)679$EYQ]YPV!6ZZLK6JPL
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M^9'Q3&S'<2]'9VDVAQ_:.(PZA69MUJ#C6)3H0=:5933I8+C:@%(6D@&LP@
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I-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
